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INTRODUCTION 
Exercise induced pulmonary hemorrhage (EIPH) in the horse has been extensively 
studied. Ribcage restriction, which is possible with saddle use, was explored as a possible 
contributing factor to EIPH in this study. Ribcage restriction forces other respiratory 
muscles, especially the diaphragm, to contribute more to tidal volume, but restriction can 
also cause additional accessory muscle recruitment when the diaphragm cannot 
adequately compensate. Exercise alone has similar muscle recruitment effects, so the 
stresses induced by the presence of both exercise and restriction were expected to be 
greater than either alone. It was also suspected that the compounded effects of both 
restriction and exercise could include other uncharacterized effects, and possibly initiate 
stronger or other compensatory mechanisms. The combined stress, which is both 
physiological on the body system and mechanical on the tissues involved, is suspected of 
contributing to EIPH. Necropsies done on horses suspected of dying from EIPH 
confirmed ruptured blood vessels in the lung tissues. The ruptured vessels could be either 
due to acute forces on the lungs or the blood vessels, or a combination. In these studies 
doxapram stimulated breathing with ribcage restriction increased blood viscosity 
(hematocrit), cardiac output, and pulmonary circulation pressure. These factors, possibly 
coupled with unusual forces on the lung tissue (not directly measured here), were 
hypothesized to be significant contributing causes ofEIPH. This study did not attempt to 
directly prove correlation of equine EIPH and ribcage restriction, but to examine the 
physiological changes involved in doxapram stimulated breathing and ribcage restriction. 
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In a significant corollary of this investigation, exercise was simulated in the 
anesthetized canine. The successful development of a canine model of EIPH would 
expedite the study of this and many other exercise-related respiratory phenomena. 
Canines are extensively used in research, and so are well characterized and well suited for 
biological modeling. They are less expensive and cumbersome to work with than horses, 
and they allow for much more invasive procedures than humans. Limitations of the model 
include pharmacological complexity during the experiment, respiratory effects due to 
anesthesia during the interpretation of results, and adaptation of the model to the 
physiological system of interest. 
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LITERATURE REVIEW 
The literature review is divided into three sections: 1) relevance and justification, 
2) pharmacology, and 3) ribcage restriction. The first section includes information on 
EIPH, the relevance of this study to medicine, and the justification for using the canine 
model. The section on pharmacology includes anesthetic choice and information 
regarding sodium pentobarbital. There is not yet extensive literature on doxapram, so this 
drug is discussed in the Experimental Procedure, as relevant characterization work was 
executed in support of this thesis. The section on ribcage restriction describes the use of 
respiratory muscles under various breathing conditions. The third section on 
pharmacology justifies the choice of anesthetic and stimulant, and describes the relevant 
pharmacology. 
Relevance and Justification 
Necropsies done on horses suspected of dying from EIPH demonstrated ruptured 
blood vessels in the lung tissues indicative of alveolar bleeding 1. The ruptured vessels 
could be either due to acute forces on the lungs or the blood vessels, or both. The 
propensity to rupture may also have environmental or genetic contributing factors. 
Anesthetizing the canines allowed for more invasive procedures in this study, and 
although portable blood sampling devices exist for monitoring exercising animals 2, it was 
advantageous to confine this preliminary study to the laboratory. 
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Pharmacology 
Pharmacological considerations were critical in this study because it was important 
to maintain similar levels of anesthesia, both among dogs in the experimental group and 
for each individual dog for the duration of the study. This was complex because of the 
antagonistic nature of anesthetic and doxapram. Doxapram in high enough doses will 
bring a dog out of barbiturate anesthesia through direct central nervous system 
stimulation. Recovery from barbiturate anesthesia requires a higher dose than for gas 
anesthesia, so undesired recovery is not as great of a concern using pentobarbital. 
Recovery from gas anesthesia is enhanced by the more rapid removal of the volatile drug 
from the blood due to increased respiration rate. 
These were the concerns regarding the use of doxapram in conjunction with gas 
anesthesia: 1) doxapram is used to accelerate gas anesthesia recovery, 2) doxapram affects 
respiration rate, making it difficult to reliably control gas anesthesia, 3) unassisted 
breathing was preferred over mechanical ventilation for determining pulmonary 
mechanics effects, and 4) doxapram may have its effects decreased due to changes in 
diaphragmatic contractility. Isotlurane and halothane both cause a marked decrease in 
diaphragmatic strength, and these effects were shown in the rat to be due to vascular 
changes in the diaphragm at the arteriole level 3. It was important to eliminate a weakened 
diaphragm as a factor in these experiments, where increased diaphragm recruitment was 
necessary to compensate for the restricted ribcage. In addition, it was best to avoid the 
effects of mechanical ventilation so that all respiratory muscles could respond in as close 
to normal a physiological manner as possible to the experimental conditions, and allow 
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the various lung volumes to fluctuate in response to compensatory mechanisms. The 
amount of gas anesthesia was also of great concern, because the use of doxapram would 
increase minute volume, and make consistent dosing difficult. 
Pentobarbital was chosen over other barbiturates because it is well characterized in 
the literature, and studies regarding its respiratory effects could be referenced to assist in 
explaining observations during the various experimental conditions. 
In light pentobarbital anesthesia there is the possibility of volume- or flow-related 
excitation of inspiratory activity. Respiratory activity, for many reasons, changes over 
time with pentobarbital sodium, as discussed in greater detail below. It was advantageous 
to keep experiments short to minimize the long-term physiological changes due to 
prolonged barbiturate anesthesia. When 20 mg/kg pentobarbital was administered 
intravenously to mixed-breed dogs, it had a rapid disposition half-life of 2.82 minutes, an 
elimination half-life of361 minutes, and a plasma concentration of28.3±6.84 ug/mL after 
1 minute 4. With an initial dose of25 mg/kg and typical experiment duration of less than 
180 minutes, the minimum plasma concentration of pentobarbital in this experiment's 
dogs would have maintained an acceptable anesthetic depth. 
In a study on increasing pentobarbital doses in cats starting at 3 5 mg/kg in 6 mg/kg 
increments until death, there were several findings that could be relevant to this study 5. 
Although the depth of anesthesia was much _greater in this cat study, there are certain 
guiding principles that probably apply to dogs, as well . There was a universal decrease in 
frequency of breathing, but the tidal volume response varied among individual cats. There 
was an increase in arterial pCO2. There was no change in excitation-contraction coupling 
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in the diaphragm with increasing depth. The diaphragm geometry was fixed, and its 
mechanical advantage in causing airflow was independent of depth as well. Since depth 
of pentobarbital anesthesia in the dogs was not as variable as in the cat study, it may be 
safe to say that these facts held true for this dog study. 
Pentobarbital caused reduced tidal volume and respiratory rate, and perhaps 
decreased sensitivity to increased blood pC02, but generally there were not significant 
changes in blood gas values 6. 
In another pentobarbital study 7, electromyograms of various inspiratory and 
expiratory muscles were recorded from prior to anesthesia induction to four hours after 
induction. Barbiturate levels and arterial pC02 were maintained at constant levels 
throughout the study. Immediately after induction, phasic activity disappeared in all 
expiratory muscle groups studied, but phasic activity was maintained in all inspiratory 
muscles for the duration of the study. Between thirty-five minutes and 2.5 hours after 
induction, most expiratory activity returned, with the notable exception of the interior 
intercostal muscles. Esophageal pressures became more negative, and gastric pressures 
more positive, but transdiaphragmatic pressure was constant. Changes in ribcage area 
increased with the increased expiratory muscle activation. Expiratory muscle activity 
appeared to return in the following order: triangularis sterni, transversus abdominus, 
external oblique abdominus, and internal intercostal. Abdominal cross-sectional area 
changes were more complex, first increasing then decreasing over the course of the 
experiment. The overall effect was an increase in tidal volume with constant breathing 
frequency. Collecting EMG data on the internal intercostal muscles would thus be an 
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important aspect of a future study that involves more detailed examination of chest-wall 
mechanics. It may also be of value to wait approximately an hour after induction and 
maintain depth with constant pentobarbital infusion, so that expiratory muscle activity 
reaches a constant level, even if it is not the same as in the awake state. 
A study specific to intercostals 8 found that with increasing pentobarbital anesthetic 
depth, parasternal activity increased slightly, costal diaphragm activity was stable, and 
external intercostal and levator costae activities decreased, with associated lateral ribcage 
motion decrease. Tidal volume and frequency decreased, and pCO2 increased with time, 
although the effects were minimized in dogs breathing air, rather than supplemental 
oxygen. 
Ribcage Restriction 
The diaphragm is the primary respiratory muscle, but the intercostal muscles 
contribute to the tidal volume as well. With ribcage restriction, the intercostal 
contribution is limited, and some compensatory mechanisms may be expected, such as 
increased abdominal displacement, which would be an indicator of greater diaphragmatic 
contribution to the tidal volume. When these compensatory mechanisms are inadequate 
for the needs of the animal, the impaired respiration may cause problems, but even in the 
absence of problems, there are marked physiological changes. 
In a human study of mild ribcage restriction (vital capacity reduced by less than 
25% ), it was found that total lung capacity was reduced, but that there was not a change in 
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expiratory flow rates until restriction was increased 9 . This study also found that 
increasing the restriction also increased the flow rates. 
In exercising, conscious humans, ribcage restriction with a corset from the sternal 
angle to the bottom third or fourth rib, caused a reduction in all lung volumes 10. Refer to 
Table 1. In addition, Hussain et al also found that ribcage restriction did significantly 
affect exercise performance, and that although the diaphragm was more active than in the 
control, the transdiaphragmatic pressure changes during respiration were consistent. The 
a e ec so n T bl 1 Effi t f 'b cage res nc 10n m exerc1smg umans t . t' h 10 
Control Ribcage Percent 
restriction change 
Vital capacity 4.98±0.29 3.56±0.20 -28 .5% 
(L) 
Total lung capacity 6.46±0.45 4.20±0.33 -35 .0% 
(L) 
Functional residual capacity 2.97±0.27 1.86±0.22 -37.4% 
(L) 
Residual volume 1.46±0.15 0.98±0.10 -32.9% 
(L) 
Dynamic lung compliance 0.205±0.014 0.160±0.011 -22.0% 
(L/cmH2O) 
method of restriction differs significantly from this study, where the posterior ribcage was 
effectively restricted by the dorsal recumbency position, and the canvas belt only 
restricted the ribs crossing the xyphoid plane, but similar reductions should be expected 
when compared with a dog in its normal posture. 
With increasing lung volume from residual capacity to total lung capacity in the 
human, gastric pressure stayed constant, but pleural pressure fell in response to declining 
diaphragmatic contractility, and also declining transdiaphragmatic pressure 11 . 
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In the human, an inelastic thoracic corset extending from the axillae to the xyphoid 
had the effects in Table 2. In both studies summarized in Tables 1 and 2, vital capacity, 
total lung capacity, functional residual capacity, and residual volume decreased 
significantly. Any variability seen in the values when comparing the two data sets, such 
as residual volume, is due to the placement of the restricting corset. 
a e ec so n T bl 2 Effi t f 'b cage res nc 10n m e uman t t 'thh 12 
Parameter Control Ribcage Percent 
restriction change 
Vital capacity 6.07±0.70 3.86±0.47 -36% 
(L) 
Total lung capacity 7.91±1.11 5.46±0.87 -31% 
(L) 
Functional residual capacity 3.99±0.90 2.88±0.80 -28% 
(L) 
Residual volume 1.83±0.51 1.61±0.51 -12% 
(L) 
Maximal expiratory flow at 50% TLC 3.0±0.8 4.4±1.2 +47% 
(Lis) 
Airway resistance 0.089±0.026 0.094±0.022 +5 .6% 
(kPa·L-1·s) 
Specific airway conductance 
(f1·kPa-1) 
2.67±0.59 3.30±0.85 +24% 
In another human study, it was found that ribcage and diaphragm contributions to the 
tidal volume varied among individuals, but that in general increasing chemical drive, 
caused by CO2 rebreathing, increased the ribcage contribution to the tidal volume relative 
to the diaphragm 13 . In the same study, restriction of the ribcage caused more increase in 
lung and respiratory elastance than did abdominal strapping. In addition, ribcage 
restriction increased the inspiratory muscle force of contraction and also increased 
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airflow, with greater restriction causing increased contractility. It decreased tidal volume 
and inspiration and expiration duration, as well as having effects on the breathing pattern. 
It is believed that neural mechanisms (such as vagal irritant receptors in the lung), not 
chemical, are responsible for theses changes 14. 
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EXPERIMENTAL PROCEDURE 
The experimental procedure is divided into four sections: pharmacology, 
experimental design, materials, and methods. The pharmacology section describes 
preliminary work regarding .the appropriate dosing of doxapram for these studies and 
interactions with pentobarbital. Experimental design describes the approach and provides 
a detailed time course for the dog studies and individual experiments. 
Pharmacology 
At the time the work in support of this thesis was initiated, literature on the 
physiological effects of doxapram was not extensive, unlike pentobarbital. Both 
pentobarbital and especially doxapram have varying degrees of effect, even in dogs of the 
same breed and sex. To make an appropriate comparison between the restricted and 
unrestricted ribcage doxapram experiments, it was important to elicit very similar 
reactions consistently. For this reason, there were several dogs used only to characterize 
with the effects of various combinations of pentobarbital and doxapram. 
Doxapram had some unpredictable effects, with the same dose (mg/kg) having 
greater or lesser effect, in either respiration or anesthetic depth, in apparently similar dogs. 
Dogs that were more active when awake were more greatly affected by doxapram, while 
more lethargic or fatter dogs required a larger dose to elicit similar responses observed in 
their more active counterparts. The maximum dose of doxapram never exceeded the 
recommended dose on the label (5 mg/kg). 
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Reduced respiratory stimulation was observed in subsequent doxapram injections, so 
the second injection had to be increased appropriately. The recommended 5 mg/kg dose 
was used for the second injection, and 3. 7 5 mg/kg was used for the first. Increasing the 
dose above 5 mg/kg caused the anesthetic depth to become very light, even with the 
reduced ventilatory effect. In this way, the two doxapram experiments were kept as 
similar as possible. 
Preliminary studies indicated that immediately following injection with 5 mg/kg 
doxapram, tidal volume and respiration rate increased immediately, with tidal volume 
increasing then decreasing to levels still much higher than normal. Approximately thirty 
seconds after injection, both the rate and tidal volume stabilized at exercise-like levels, 
and remained so for approximately three minutes. This was adequate time for the reliable 
gathering of all desired physiological data. 
There are pharmacological complications due to variability among individual dogs. 
Even if originally at the same anesthetic depth and given identical doses of doxapram, 
some dogs would become much lighter than others within the same time period. 
Additional pentobarbital was administered to maintain anesthetic depth, and doses were 
titrated based on breaths per minute, palpebral reflex, and pedal withdrawal reflex. It was 
necessary to maintain pentobarbital anesthesia with additional intravenous injection in 
experiments having more than a couple of hours duration, and this was complicated by the 
doxapram experiments, which in some dogs can alter the respiratory pattern for long 
periods if unchecked by an additional dose of pentobarbital. 
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Pentobarbital doses in these studies decreased activation of the external intercostal 
and levator costae muscles. Tidal volume and frequency did not decrease, nor did arterial 
pCO2 increase with time, as is observed with deep pentobarbital anesthesia. 
Experimental Design 
The six dog studies were randomly divided into two different groups based upon the 
experiment order, and these groups are referred to in the thesis as either "restriction first" 
or "doxapram first" based on the definitions in Table 3. The randomization was necessary 
to detect any long-term effects of doxapram or restriction on the physiological parameters 
not readily apparent during study execution. 
a e e 1mt1on o t T bl 3 D fi . . f h e expenmenta grou os 
Group name Restriction first Doxapram first 
Dog numbers ( order of study execution) 1, 3, 4 2, 5, 6 
Control 
Experiment order Restriction Doxapram Doxapram Restriction 
Doxapram with restriction 
The four different breathing experiments all followed specific timelines. Time 
zero for each study was immediately after the completion of the dog preparation and 
initiation of computer data acquisition on all channels. Because the computer data 
acquisition system constantly collected most of the data, the studies were interrupted by 
doxapram injections, restriction events, and blood sampling. The four different 
experiments immediately followed one another after the initial study preparation 
(described in "Methods"). Refer to Tables 4 and 5. 
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T bl 4 N . 1 t d t a e omma s u 1y 1me course o fth t . f fi e res nc 10n 1rst group 
Study Experiment Event Event definition 
time time abbreviation Italics indicate that blood was sampled 
(min.) (min.) 
Control 
0 0 Base 1 Baseline 1 within 5 min. of acquisition initiation 
10 10 Base 2 Baseline 2 
Restriction 
15a 
-0.5 R-0.5 30 seconds prior to restriction 
15 .5° 0 R Immediately followin~ restriction 
20.5 5 R+5 5 minutes after restriction 
25 .5 10 R+lO 10 minutes after restriction 
25.75° 10.25 Re Restriction release 
30.75 15.25 Re+5 5 minutes after release 
35.75 20.25 Re+l0 10 minutes after release 
Doxapram 
40.75a 
-0.5 1-0.5 30 seconds prior to injection 
41.25° 0 I Immediatelyfollowin~ injection 
41.75 0.5 l+0.5 30 seconds after injection 
42.25 1 I+l 1 minute after injection 
43.25 2 l+2 2 minutes after injection 
46.25 5 l+5 5 minutes after injection 
51 .25 10 l+10 10 minutes after injection 
56.25 15 l+15 15 minutes after injection 
Doxapram with restriction 
61.25a 
-0.5 RI-0.5 30 seconds prior to restriction, then injection 
61.75° 0 RI Immediately followin~ restriction, then injection 
62.25 0.5 Rl+0.5 30 seconds after injection 
62.75 1 Rl+l 1 minute after injection 
63 .75 2 RI+2 2 minutes after injection 
66.75 5 RI+5 5 minutes after injection 
71.75 10 RI+l0 10 minutes after injection 
72c 10.25 Re Restriction release 
77 15.25 Re+5 5 minutes after release 
82 20.25 Re+l0 10 minutes after release 
a The 5 min. was added to the total time to allow for experiment change. 
b The 0.5 min. for experiment baseline was added to the total time. 
c The 0.25 min. was added to the total for the time required to release restriction. 
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T bl 5 N . 1 t d t a e omma s u ty 1me course o fth d e fi t oxapram Irs group 
Study Experiment Event Event definition 
time time abbreviation Italics indicate that blood was sampled 
(min.) (min.) 
Control 
0 0 Base 1 Baseline 1 within 5 min. of acquisition initiation 
10 10 Base 2 Baseline 2 
Doxapram 
15a 
-0.5 1-0.5 30 seconds prior to injection 
15 .5b 0 I Immediately following injection 
16 0.5 l+0.5 30 seconds after injection 
16.5 1 l+l 1 minute after injection 
17.5 2 l+2 2 minutes after injection 
20.5 5 l+5 5 minutes after injection 
25 .5 10 l+10 10 minutes after injection 
30.5 15 l+15 15 minutes after injection 
Restriction 
35 .5a 
-0.5 R-0.5 30 seconds prior to restriction 
36b 0 R Immediately.following restriction 
41 5 R+5 5 minutes after restriction 
46 10 R+lO 10 minutes after restriction 
46.25c 10.25 Re Restriction release 
51.25 15 .25 Re+5 5 minutes after release 
56.25 20.25 Re+l0 10 minutes after release 
Doxapram with restriction (also referred to as the coupled experiment) 
61.25a 
-0.5 RI-0.5 30 seconds prior to restriction, then injection 
61.75b 0 RI Immediately.following restriction, then injection 
62.25 0.5 RI+0.5 30 seconds after injection 
62.75 1 RI+l 1 minute after injection 
63 .75 2 RI+2 2 minutes after injection 
66.75 5 RI+5 5 minutes after injection 
71.75 10 RI+l0 10 minutes after injection 
72c 10.25 Re Restriction release 
77 15 .25 Re+5 5 minutes after release 
82 20.25 Re+l0 10 minutes after release 
a The 5 min. was added to the total time to allow for experiment change. 
b The 0.5 min. for experiment baseline was added to the total time. 
c The 0.25 min. was added to the total for the time required to release restriction. 
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Materials 
Physiological parameters were constantly monitored in each sodium pentobarbital 
anesthetized dog in four different breathing conditions: 1) unrestricted ribcage, normal 
breathing, 2) restricted ribcage, normal breathing, 3) unrestricted ribcage, doxapram 
stimulated breathing, and 4) restricted ribcage, doxapram stimulated breathing. These 
breathing conditions are referred to as experiments, and the total of all experiments 
performed on each dog is referred to as a study. 
The ribcage was restricted using a rigid canvas belt and a buckle that allowed for 
continuous adjustment. The belt was positioned just cranial to the xyphoid in a transverse 
plane perpendicular to the body axis. For restricted breathing, the belt was tightened until 
the ribcage was 90% of the normal relaxed circumference. Exercise induced respiratory 
responses were simulated using doxapram, which is used in human and veterinary 
medicine to increase the respiratory rate and thereby shorten recovery from gas anesthesia. 
Physiological parameters were constantly monitored throughout the experiments 
using a data acquisition system developed by Biopac Systems, Inc. The system included 
both the data collection and analysis software called Acknowledge™, and the hardware 
used to convert analog signals from biosensors into digital signals, which were recorded 
by computer. The interface of the system with the PC was a standard board that fit into an 
expansion slot on the motherboard. A Hewlett-Packard Pavilion 6460 TM was used for 
acquisition, which had a 400MHz Pentium II processor, 96 MB of DRAM, and a 9 GB 
hard drive, and was well within the requirements for the Biopac system. 
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The three types of sensors used for the acquisition were a differential pressure 
transducer pneumotach, EKG apparatus, and three Statham™ differential pressure 
transducers, which connected to appropriate devices to interface with the dog. The 
pneumotach and EKG leads were attached to the Biopac hardware using specialized 
analog/digital converters, but the pressure transducers connected directly to standard 
analog/digital boxes using adapters. 
The pressure transducers were used for collecting data on three different parameters: 
1) carotid artery pressure (CAP), 2) esophageal pressure (EP), and 3) airway pressure 
(AP). The CAP pressure transducer was continuous with a carotid artery cannula via the 
polyethylene tubing. There was a three-way stopcock that was used to take arterial blood 
samples and reintroduce heparinized saline (3 IU/mL) into the cannula to prevent clotting. 
The EP transducer interfaced with a polyethylene tube filled with distilled water and 
inserted into an esophageal cannula with its end immediately adjacent to the distal hole of 
the cannula. The esophageal pressure measured was just cranial to the gastric sphincter. 
The AP pressure transducer interfaced with a distilled-water-filled tube inserted through 
the endotrachael tube to a point just cranial of the trachael bifurcation, as estimated from 
the exterior anatomy of each dog. 
After anaerobic blood sampling, a blood gas analyzer was used for blood pH, pCO2, 
and pO2 determination. An Adams Autocrit TM centrifuge and standard glass capillary 
tubes were used for hematocrit determination. 
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Methods 
An angiocatheter was inserted into the cephalic vein of one of the thoracic legs of 
each dog. Anesthesia was induced with a 25 mg/kg intravenous bolus injection of sodium 
pentobarbital, and anesthesia was maintained throughout the experiment by administering 
more barbiturate if needed, as determined by stretching and palpebral and pedal 
withdrawal reflexes. After the administration of doxapram, it was necessary to use 
pentobarbital to titrate the dog to the original anesthetic depth, as determined by 
respiration rate. Usually this dose was approximately 5 mg/kg. The experiments were 
short enough in duration that administration of additional pentobarbital would not have 
been necessary to maintain a constant level of anesthesia, if it were not for the use of 
doxapram. 
After the induction of anesthesia, a size IO endotrachael tube was inserted to 
maintain the airway, and to facilitate the measurement of both airflow and airway 
pressure. Normal unassisted breathing patterns were present. Body temperature was 
maintained using a recirculating water heating pad. The neck area was clipped, and the 
carotid artery was exposed and isolated via a single 6 cm skin incision and subsequent 
blunt dissection. A cannula was introduced approximately IO cm into the carotid artery, 
and tied to anchor the cannula within the artery. The artery was tied off cranial to the site 
of insertion only if there was substantial bleeding around the cannula puncture. 
Pressure transducers used for the measurement of airway, esophageal, and carotid 
arterial pressures were calibrated at two points - 0 mrnHg and then 100 mrnHg - in the 
following manner. A manometer was placed at the same level as the subject and 
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transducers, and the outlet attached to the ends of polyethylene tubing at the point where 
the respective cannulas attached during the experiment. The 0 mmHg reading was taken 
when the pressure transducer was open to air, and the 100 mmHg reading when the 
manometer was pressurized and attached to the point of cannula attachment. Care was 
taken to ensure that fluid was continuous throughout the pressure transducer-cannula 
system. It was possible to adjust the baseline reading on all pressure transducer lines to 
zero by adjusting the height of the transducer with respect to the dog. This was done at 
the beginning of each experiment, and verified again at the end. The experiment was 
short enough in duration that no significant deviation occurred. 
The calibration of airflow and tidal volume was more complex. Two-point 
calibrations were performed at 0 and 5 LPM airflow using a flowmeter, and then a series 
of volumes of air were passed through the pneumotach from 100 to 400 mL in 50 mL 
increments in triplicate, using a large syringe. Later, these curves were integrated and the 
known values assigned to the calculated areas. A linear plot was then constructed for each 
dog relating area values to known volumes. In this way, any factors contributing to 
variations in pneumotach readings were eliminated. By performing the same calibration 
procedure after each dog, it was found that there was no significant variation in either the 
airflow curve or area over the course of one experiment. 
The preparation time did vary for different dogs, and this is best illustrated by the 
duration of each experiment, which varied from about 1.5 to 3.2 hours. Preparation time 
was the only factor that influenced the total duration, as once the first blood sample was 
drawn, the schedule was adhered to rigorously. In the preparation of dogs 1-3, a Swan-
20 
Ganz catheter was inserted into the jugular vein in an attempt to reach the pulmonary 
artery for pulmonary artery wedge pressure measurement, venous blood sampling, and 
cardiac output measurement. This was abandoned after the results were not repeatable, 
due to the age and associated rigidity of the catheters. Table 6 shows the total time 
duration of each study. 
T bl 6 T d a e 1me urat1on fr om m1tiat1on t hr h h fi ougl t e ma expenment 
Dog number Duration (minutes) 
1 170 
2 143 
3 192 
4 95 
5 92 
6 97 
Once all sensors were in place and data acquisition was initiated, the series of four 
experiments were performed on each dog. A total of ten anaerobic blood samples were 
withdrawn periodically from the carotid artery and placed on ice. Upon study termination, 
the anaerobic arterial blood samples were immediately analyzed for p02, pC02, pH, and 
triplicate hematocrit determination. Data collected by computer was manipulated 
depending upon the physiological parameter, as discussed in Data Analyses. This 
manipulated data from the experiments was then summarized in Appendix B. The 
baseline values from the study control periods were summarized in Appendix A. 
Appendix C contains averages, standard deviations, and covariance values. 
21 
DATA ANALYSES 
Data analyses are organized according to the physiological parameters examined. 
These are categorized into three groups: 1) breathing pattern, 2) pulmonary mechanics, · 
and 3) cardiovascular. Breathing pattern includes analyses of respiration rate, inspiration 
time, expiration time, and the inspiration time/ expiration time ratio . Pulmonary 
mechanics examines airway and esophageal pressures, tidal and minute volumes, and 
compliance work. The cardiovascular parameters include heart rate, arterial blood 
pressure (systolic and diastolic), and blood parameters (arterial blood oxygen and carbon 
dioxide partial pressures, arterial blood pH, and arterial blood hematocrit) . 
There were two general types of analysis performed. The first type compared 
response to experimental conditions by the individual physiological parameter. This was 
done graphically, and the results are the figures appearing below. The second type of 
analysis compared the data from the two groups (doxapram first and restriction first) with 
the group of all six dogs. The numerical results of this analysis appear in tabular form in 
Appendix C, and are discussed in the text associated with the physiological parameters 
where appropriate. 
Each physiological parameter has a figure with analysis in the body of the text, a 
table of baseline values in Appendix A, a table of experimental data in Appendix B, and 
the average data used for the figures appears in Appendix C. Each data point appearing in 
the appendixes is associated both with an individual dog, and a point in time during the 
course of the initial control period or subsequent three experiments. Each point in time 
has a numerical value (in minutes) and an "event", which describes the experimental 
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purpose of that point in time. Refer to Tables 4 and 5 above, and note that the same event 
abbreviations and experiment times appear in the three appendixes. 
The figures have the study baseline plotted along with data points for the three 
experimental conditions. Baseline values refer to the values taken at time O and 10 
minutes during the control period, prior to any experimental breathing conditions. 
Baseline averages were calculated and plotted for each data set. The values were 
collected from the initial control period for each canine, and so they are a reflection of the 
individual dogs' responses to pentobarbital anesthesia, as well as anesthetic depth. The 
baseline averages appear on each appropriate plot for reference. Each breathing 
experiment also had a baseline value taken thirty seconds prior to experiment initiation for 
comparison to the study baseline. With the exception of the blood composition 
parameters, all experiments have data points connected in chronological order for trend 
analysis. These curves are constructed from individual time points that represent the 
average of all relevant data from the six dogs. 
It was informative to take into consideration the averages for each individual data 
set, as considerable variation among individual dogs did exist. Table 7 summarizes 
baseline values, and the data for the individual dogs appears in Appendix A The 
breathing pattern and pulmonary mechanics parameters had considerable variability, with 
the exception of compliance work, which was very similar when comparing the three 
groups. All of the cardiovascular parameters had very similar baseline values, with the 
exception of systolic blood pressure. 
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Table 7: Baseline Values for Each Data Set 
Parameter (units) Restriction Doxapram Both groups 
first group first group combined 
Airway Pressure (mmHg) 4.31 4.01 4.16 
Esophageal Pressure (mmHg) 6.20 5.12 5.66 
Inspiration Time (s) 1.65 1.92 1.78 
Expiration Time (s) 4.66 6.82 5.74 
Inspiration / Expiration Ratio 0.35 0.28 0.31 
Respiration Rate (BPM) 12.8 6.5 9.7 
Specific Tidal Volume (mL/Kg) 9.6 12.9 11.2 
Specific Minute Volume (mL/Kg min) 99 84 92 
Compliance Work (mmHg L) 1.11 1.15 1.13 
Heart Rate (BPM) 134 134 134 
Systolic Pressure (mmHg) 145 188 166 
Diastolic Pressure (mmHg) 111 119 115 
Blood p02(mmHg) 93.7 95 .8 94.7 
Blood pC02 (mmHg) 42.7 40.0 41.6 
Blood pH 7.319 7.362 7.340 
Blood Hematocrit (%) 41.4 38.4 39.9 
Breathing Pattern 
Breathing pattern analysis is divided into respiration rate, the two components 
inspiration time and expiration time, and the ratio of the inspiration time over expiration 
time. 
Respiration rate 
Respiration rate was critical to appropriate dosing of pentobarbital to maintain 
anesthetic depth, and for monitoring doxapram response. Respiration rate (Figure 1) was 
determined from the pneumotach channel by calculating the breaths per minute from the 
time duration of three of five consecutive breaths, and averaging. These averages are the 
numbers that appear in Appendix Table B 1. This method of calculating respiration rate 
was chosen primarily because the duration of the maximum doxapram effect was much 
less than one minute. 
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Figure 1: Respiration rate 
Dogs 1, 4, and 5 all had lower respiration rates than dogs 2, 3, and 4 in the final 
coupled experiment. This likely had to do with a factor independent of experimental 
. design, because this division does not correspond to the doxapram or restriction first 
grouping. Dog 3 had considerably faster respiration than all other dogs until the final 
coupled experiment. Average baseline values for the experiments were consistently 
higher than the original study baseline. The study baseline was taken more immediately 
following the pentobarbital anesthesia induction, and so lower values were expected. 
A way to quantify the individual variability within a group (such as doxapram 
first) for the duration of an experiment (such as restriction), is to average the covariance 
values that appear in Appendix C. In the restriction first group, the covariance values 
(CVs) for the restriction experiment were much higher (average of 92) than those in the 
doxapram experiment (average of 56). When restriction followed the doxapram 
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experiment in the doxapram first group, the restriction effect had much less variability 
among the individual dogs (average CV of 45). Refer to Table 8. In the doxapram first 
group, the doxapram may have made the respiration rate more consistent among 
individual dogs during restriction than if there had not been a preceding doxapram 
injection. 
T bl 8 C a e f h ompanson o t e average respiration rate covariances 
Experiment Restriction first Doxapram first Both groups group group 
Doxapram 56 44 69 
Restriction 92 45 82 
Doxapram with 37 72 52 
restriction 
Inspiration time 
Inspiration time is the time duration from the onset of a breath to the end of 
inspiration and the beginning of expiration, as measured on the pneumotach channel. 
Each value in Appendix Table B2 is the average of three values taken within five breaths, 
and these correspond to the same set of waveforms used for respiration rate. It is a 
measure of the speed with which a breath is taken. The shorter the inspiration time, the 
more quickly and forcefully the inspiratory muscles are contracting. 
Experiment baseline values were again faster than the study baseline, as expected. 
Dog 3 did not have any outstanding characteristics, as it did with respiration rate. 
Average inspiration time remained virtually unchanged throughout the restriction 
experiment; however, when coupled with doxapram, the restriction release effect is 
evident in Figure 2. The effect of the first doxapram injection was more drastic than the 
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second (comparing the "Doxapram" and the "Both" trends), but the second injection 
elicited a faster overall inspiration time, because the experiment baseline was faster for the 
coupled experiment. In either experiment involving doxapram injection, values did not 
return to baseline within the experiment time duration. In the restriction experiment, 
release was evident in the curve, but in the coupled experiment, it was not. 
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Figure 2: Inspiration time 
Expiration time 
Expiration time (Figure 3) is the time duration from the initiation of exhalation to 
the initiation of the following breath, as measured on the pneumotach channel. Each 
value in Appendix Table B3 is the average of three values taken within five breaths, 
which correspond to the same breaths used for the respiration rate determination. Because 
it is longer in time duration by its definition, expiration time would have more drastic 
change in duration than would inspiration time, with changing respiration rate. Dog 3, 
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which had an exceptionally fast respiration rate, exhibited a very short expiratory time in 
comparison to the other dogs, but its inspiratory time was not exceptional. 
In general, the CV s for the restriction first group were much higher in the 
restriction alone and doxapram alone experiments, than were the CV s for the doxapram 
first group. Refer to Appendix Table C3. 
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Figure 3: Expiration time 
Ratio of inspiration time / expiration time 
Because there were changes in both inspiration and expiration times, a ratio was 
used to determine the relative magnitude of the changes (Figure 4 and Appendix Table 
B4). For example, an increase in the ratio would indicate that the expiration time 
decreased, and by extension that muscles responsible for increased respiration rate were 
stimulated. As expected, Dog 3 had a much higher baseline ratio, and it remained high 
until the final coupled experiment. Note that both doxapram experiments caused an 
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increase in the ratio over the study baseline, and that restriction alone reduced the ratio 
below baseline. All three experiments caused an increase in ratio over the experiment 
baseline, and the coupled experiment had a change greater than either of the other two 
experiments combined. 
1.20 
1.00 
i 0.80 
= 0 
u 
"' 0.60 ~
"' a 
i= 0.40 
0 .20 
0.00 
-1 0 
El Doxapram 
- - - Restriction 
- -A--- Both 
················· Baseline 
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Experiment Time (minutes) 
Figure 4: Ratio of inspiration time I expiration time 
Pulmonary Mechanics 
Pulmonary mechanics includes airway and esophageal pressures, tidal and minute 
volumes, and compliance work. 
Airway pressure 
Airway pressure (AP) is the pressure difference (in mrnHg) between the inspired 
and resting pressure values, and it represents the driving force for air movement in and out 
of the lungs (Figure 5). Each number in Appendix Table BS represents an average of 
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three readings taken within five respirations centered on the event of interest. The 
exception to this is the reading immediately following the injection or restriction 
initiation, which requires that the three readings be taken immediately following the 
experiment initiation. 
Dogs 4, 5, and 6 had high airway pressure values in comparison to the remainder 
of the dogs. The doxapram first group exhibited much higher CV s throughout the studies 
than the restriction first group, and this change is independent of the initial study baseline 
observations. Refer to Appendix Table CS . It is possible that doxapram caused great 
individual variation in subsequent airway pressure readings, that the restriction experiment 
in the restriction first group had a moderating effect on airway pressure, or a combination 
of these. It is also possible that the effects are highly dependent on the individual dogs 
being studied. It is interesting to note that restriction alone caused a return to the study 
baseline, and this was maintained after restriction release. 
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Figure 5: Airway pressure 
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Esophageal pressure 
Esophageal pressure (EP) is the pressure difference (in mmHg) between inspired 
and resting pressures. It is considered an approximation of pleural pressure and the 
values, along with tidal volume, are used in the calculation of compliance work. See 
Figure 6. 
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Figure 6: Esophageal pressure 
Dogs 4, 5, and 6 showed elevated baseline with esophageal pressure, as they did 
with airway pressure. Dog 3 also had an elevated baseline compared to dogs 1 and 2, and 
it is interesting to note that dog 3 had a high respiration rate. Esophageal pressure was 
high despite a relatively low airway pressure in the dog that had the fastest respiration 
rate. With deeper anesthesia, both esophageal and airway pressures were elevated in dogs 
4, 5, and 6. 
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Restriction alone had little effect on esophageal pressure. Doxapram had a very 
drastic effect with the first injection (with dog 1 having by far the most drastic), but the 
second doxapram experiment either had less effect, or the effect was tempered by 
restriction. 
Specific tidal volume 
Tidal volume (Figure 7) was determined by integrating three of five consecutive 
inspiration waveforms of the pneumotach, and averaging. Linear calibration curves were 
constructed for each dog that correlated integration values with volumes. 
Tidal volumes were then divided by the mass (in Kg) of the dog to make the data more 
comparable (specific tidal volume). 
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Figure 7: Specific tidal volume 
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Specific tidal volume increased greatly with doxapram alone and decreased below 
the initial study baseline with restriction. Although the curve for the coupled experiment 
mimics the doxapram experiment curve in shape, it is actually farther below the study 
baseline than the restriction experiment curve. The combined stress of doxapram and 
restriction caused a decrease in tidal volume. Dog 3, which had the high respiration rate, 
also had comparatively low tidal volumes. These observations suggest that minute 
volume would be informative. 
Specific minute volume 
Specific minute volume (Figure 8) was calculated by multiplying the respiration 
rate and specific tidal volume averages. Note that at approximately ten minutes following 
experiment initiation, all three experiments' values converged on a single minute volume 
value, slightly higher than the study baseline, and very close to each of the experiment 
baseline values. 
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Figure 8: Specific minute volume 
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The nearly linear decline in minute volume on the doxapram experiment curve has 
two phases. In the first phase, lasting for approximately the first five minutes after 
injection, the respiration rate remains constant, and the linear decline observed in the 
minute volume curve is due primarily to declining tidal volume. When respiration rate 
begins to gradually return to experiment baseline, the tidal volume remains relatively 
constant, and eventually increases to nearly the same level as the experiment baseline. 
Minute volume remains nearly constant when comparing the three restriction 
experiments in the same figures, with slight evidence for restriction release, and even less 
evidence for restriction initiation. There is a very gradual and slight increase in minute 
volume throughout the restriction experiments. When respiration rate peaked immediately 
following restriction, the tidal volume simultaneously dropped. The tidal volume then 
gradually and linearly increased until restriction release, while the respiration rate 
remained constant. Release caused an immediate increase in respiration rate, and a 
decrease in tidal volume, which combined to cause a slight increase in minute volume. 
The dogs were able to maintain minute volume well with restriction alone. 
With the coupled experiment, the curve shape for the minute volume closely 
mimics the respiration rate curve, with restriction release causing a drop in both 
respiration rate and tidal volume. Prior to restriction release, and two minutes after 
doxapram injection, the minute volume was increasing linearly. After release, the value 
returned to the two-minute level. 
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Compliance work 
Compliance work is the work required to expand the lungs against elastic forces. 
Compliance work (Figure 9) was calculated by taking half of the product of esophageal 
pressure, an approximation of pleural pressure (peak pressure minus baseline), and tidal 
volume (not specific tidal volume). 
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Figure 9: Compliance work 
Doxapram alone caused a very significant increase in work, but when restriction 
was present, the work approximated study and experiment baseline values. Dog 1 had 
significantly higher compliance work values for the doxapram experiment, but values 
were closer to average for the remaining experiments. The reason for this is unknown, but 
it is due to the higher esophageal pressure, and it is likely it was due to incorrect 
positioning of the esophageal cannula, which corrected as the study progressed. 
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Cardiovascular 
Cardiovascular parameters examined include heart rate, arterial blood pressures 
(systolic and diastolic), blood oxygen and carbon dioxide partial pressures, blood pH and 
blood hematocrit. Blood pressures and samples were taken from the carotid artery. 
Heart rate 
Heart rate (Figure 10) was determined from the electrocardiogram channel in the 
same way that respiration rate was determined from the pneumotach. Heart rate is an 
important factor in cardiac output, but without knowing the ejection volume, cardiac 
output could not be calculated. If the ejection volume would remain the same with 
doxapram (it almost certainly increases), it can be inferred that cardiac output does 
increase in a manner at least as drastic as the heart rate. 
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Figure 10: Heart rate 
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Blood pressure 
Carotid artery blood pressure (Figures 11 and 12) was calculated by averaging 
three of five consecutive systolic and diastolic pressures, as measured from the arterial 
blood pressure channel. Although pulmonary artery pressure would be more directly 
applicable to this study, as a factor contributing to pulmonary capillary wall stress, in 
general an increase in systemic blood pressure is indicative of an increase in the 
pulmonary circulatory system. With restriction alone, restriction release caused an 
immediate decrease in both systolic and diastolic pressures. However, in the coupled 
experiment, the use of doxapram caused an increase of about half the magnitude with 
restriction release. The doxapram effect on the heart was larger with the second dose. 
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Figure 11 : Systolic pressure 
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Figure 12: Diastolic pressure 
Blood parameters 
The four blood parameters remained within normal ranges throughout all 
experiments, and the data is summarized in Figures 13-16. Hematocrit (Figure 16) was 
the only blood parameter that was the average of triplicate samples. Blood gases and pH 
were determined only once. The slight linear decline in average blood oxygen partial 
pressure values as the studies progressed did not have an impact on minute volume. As 
expected blood pH levels and pCO2 values remained in the normal range regardless of the 
challenging breathing conditions. The blood parameter most directly applicable to this 
study in its current form was hematocrit, which would increase blood viscosity and hence 
stress on the pulmonary capillary walls. During exercise, or even sympathetic nervous 
system stimulation, hematocrit is expected to increase more than it did with doxapram. 
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Figure 13 :Arterial blood oxygen partial pressure 
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Figure 14: Arterial blood carbon dioxide partial pressure 
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Figure 15: Arterial blood pH 
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Figure 16: Arterial blood hematocrit 
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CONCLUSIONS 
The quantification of the physiological effects of doxapram stimulated breathing 
coupled with ribcage restriction in the canine did not definitively demonstrate that the 
saddle could be a contributing factor in equine EIPH. The pharmacological interactions of 
doxapram and sodium pentobarbital were shown to be manageable, and it was possible to 
achieve repeatability. Even though the six subjects used in direct support of this thesis did 
not yield statistically significant results, the study did demonstrate the feasibility of using 
the anesthetized canine for further exercise-related investigations, including those related 
to EIPH. The study also demonstrated the use of doxapram to elicit a respiratory response 
similar in many ways to exercise. Although ribcage restriction did elicit responses similar 
to the literature, the model combining doxapram with ribcage restriction did not provide 
conclusive data for the physiological causes ofEIPH. 
Suggestions for further study using these same experimental conditions include: 1) 
the use of more subjects to increase statistical significance, 2) the measurement of 
abdominal pressure for transdiaphragmatic pressure calculation, 3) the measurement of 
cardiac output and pulmonary artery wedge pressure, and 4) the management of anesthetic 
depth. More rigorous and statistically significant characterization of the interaction of 
doxapram, ribcage restriction, and pentobarbital would be useful to making the 
experiments more consistent. 
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APPENDIX A: BASELINE VALUES 
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Table Al : Respiration rate baseline values (BPM) 
Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 Avg. Sdev. 
Base 1 7 7 24 6 7 5 9 7 
Base 2 6 9 27 7 7 4 10 8 
Overall Avg. and Sdev. 10 8 
Table A2: Inspiration time baseline values (s) 
Dog 1 Dog2 Dog3 Dog4 Dog5 Dog6 Avg. Sdev. 
Base 1 1.46 1.63 1.39 2.22 2.72 1.69 1.85 0.52 
Base 2 1.55 1.46 1.17 2.12 2.36 1.63 1.71 0.44 
Overall Avg. and Sdev. 1.78 0.46 
Table A3 : Expiration time baseline values (s) 
Dog 1 Dog2 Dog3 Dog4 Dog5 Dog6 Avg. Sdev. 
Base 1 6.32 6.42 1.05 6.48 5.07 8.50 5.64 2.50 
Base 2 7.61 4.93 1.05 5.42 5.46 10.52 5.83 3.13 
Overall Avg. and Sdev. 5.74 2.71 
Table A4: Ratio of inspiration time I expiration time baseline values (s, 
Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 Avg. Sdev. 
Base 1 0.23 0.25 1.32 0.34 0.54 0.20 0.48 0.43 
Base 2 0.20 0.30 1.11 0.39 0.43 0.15 0.43 0.35 
Overall Avg. and Sdev. 0.46 0.38 
Table AS: Airway pressure baseline values (mmH~) 
Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 Avg. Sdev. 
Base 1 2.96 1.23 3.64 6.12 4.39 6.07 4.07 1.89 
Base2 4.85 1.04 3.38 4.89 3.77 7.53 4.24 2.14 
Overall Avg. and Sdev. 4.16 1.92 
Table A6: Esophageal pressure baseline values (mmHg) 
Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 Avg. Sdev. 
Base 1 7.62 2.22 5.46 6.31 6.16 6.92 5.78 1.89 
Base 2 6.03 2.05 6.97 4.83 6.57 6.82 5.55 1.88 
Overall Avg. and Sdev. 5.66 1.80 
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Table A7: Specific tidal volume baseline values (mL/Kg) 
Dog 1 Dog2 Dog3 Dog4 Dog5 Dog6 Avg. Sdev. 
Base 1 14.8 15.7 5.8 10.8 11.0 13.1 11.9 3.6 
Base2 10.8 14.4 5.6 9.9 10.8 12.2 10.6 2.9 
Overall Avg. and Sdev. 11.2 3.2 
Table A8: Specific minute volume baseline values (mL/Kg min) 
Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 Avg. Sdev. 
Base 1 104 110 140 65 77 65 93 30 
Base 2 65 129 152 70 76 49 90 41 
Overall Avg. and Sdev. 92 34 
Table A9: Compliance work baseline values (mmHg L) 
Dog 1 Dog2 Dog3 Dog4 Dog5 Dog6 Avg. Sdev. 
Base 1 1.95 0.47 0.62 1.30 1.39 1.64 1.23 0.58 
Base 2 1.12 0.40 0.77 0.92 1.46 1.52 1.03 0.43 
Overall Avg. and Sdev. 1.13 0.49 
Table AlO: Heart rate baseline values (BPM) 
Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 Avg. Sdev. 
Base 1 144 126 138 132 144 126 135 8 
Base 2 132 144 132 126 126 138 133 6 
Overall Avg. and Sdev. 134 7 
Table Al 1: Systolic pressure baseline values (mmH~) 
Dog 1 Dog2 Dog3 Dog4 Dog5 Dog6 Avg. Sdev. 
Base 1 * * 141 155 161 217 168 33 
Base 2 * * 129 154 164 210 164 34 
Overall Avg. and Sdev. 166 31 
*Data not collected 
Table Al2 : Diastolic oressure baseline values (mmHg) 
Dog 1 Dog2 Dog 3 Dog4 Dog 5 Dog6 Avg. Sdev. 
Base 1 * * 117 112 121 127 119 6 
Base 2 * * 112 105 119 111 111 6 
Overall Avg. and Sdev. 115 7 
*Data not collected 
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Table Al3: Arterial blood oxygen partial pressure (mmHg) 
Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 Avg. Sdev. 
Base 1 93.9 91.7 91.5 93.4 95.8 95 .6 93.7 1.8 
Base 2 94.6 95 .2 92.6 96.1 97.2 99.2 95.8 2.3 
Overall Avg. and Sdev. 94.7 2.3 
*140 was ignored because the CO2 reading was normal, and the 0 2 probe on the blood gas 
analyzer experienced a calibration error immediately following the sample analysis. 
Table A14: Arterial blood carbon dioxide partial pressure mmHg) 
Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 Avg. Sdev. 
Base 1 43 .6 46.0 41.3 42.5 37.8 37.6 41.5 3.3 
Base 2 48 .8 37.7 37.5 42.7 44.8 38.7 41.7 4.6 
Overall Avg. and Sdev. 41.6 3.8 
T bl A15 Art . l bl d H b l' a e ena 00 p ase me va ues 
Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 Avg. Sdev. 
Base 1 7.298 7.306 7.328 7.286 7.335 7.391 7.324 0.038 
Base2 7.315 7.385 7.357 7.327 7.350 7.403 7.356 0.033 
Overall Avg. and Sdev. 7.340 0.038 
Table A16: Arterial blood hematocrit baseline values (percent ofred blood cells in blood) 
Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 Avg. Sdev. 
Base 1 41.3 42.3 43 37.8 34.7 37.3 39.4 3.3 
Base 2 44 36.7 43 39 42.3 37 40.3 3.2 
Overall Avg. and Sdev. 39.9 3.1 
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Table B 1: Respiration rate (BPM) 
D Efli oxapram ect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 I- 0.5 10 7 26 19 7 4 
0 I 35 32 35 18 27 21 
0.5 l+0.5 28 22 59 23 21 16 
1 l+1 29 27 60 22 19 9 
2 l+2 35 33 62 23 16 8 
5 l+5 40 33 61 16 9 5 
10 l+10 21 12 53 15 8 5 
15 l+15 13 9 49 13 7 5 
Restriction Effect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 R-0.5 7 10 38 8 8 5 
0 R 11 13 61 8 8 15 
5 R+5 7 12 32 13 8 7 
10 R+l0 7 13 31 12 7 11 
10.25 Re 6 21 41 9 8 25 
15 .25 Re+5 9 21 33 9 8 8 
20.25 Re+l0 9 23 42 10 8 5 
D . hR oxapram wit estnct1on Efli ect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 Rl-0 .5 12 26 27 25 9 4 
0 RI 38 76 63 36 20 26 
0.5 Rl+0.5 27 30 33 37 17 22 
1 RI+l 24 34 38 40 17 18 
2 RI+2 21 32 32 38 15 15 
5 RI+5 23 62 62 35 14 9 
10 RI+l0 20 76 62 33 11 12 
10.25 Re 14 69 50 28 11 8 
15.25 Re+5 17 36 35 25 10 8 
20.25 Re+l0 16 15 16 25 10 15 
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Table B2: Inspiration time (s) 
D Effi t oxapram ec 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 I- 0.5 1.53 1.43 1.22 1.01 2.58 1.74 
0 I 0.72 0.77 0.85 0.89 1.09 1.08 
0.5 l+0.5 0.75 0.75 0.42 0.85 1.47 1.19 
1 I+l 0.75 0.61 0.43 1.15 1.41 1.36 
2 l+2 0.70 0.57 0.43 1.31 1.67 1.44 
5 l+5 0.73 0.53 0.45 1.53 2.48 1.33 
10 l+10 1.03 1.08 0.52 1.64 2.99 1.36 
15 l+15 1.34 1.17 0.80 1.64 2.73 1.47 
Restriction Effect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 R-0.5 1.00 0.80 0.62 1.10 2.05 2.12 
0 R 1.01 0.53 0.43 1.29 1.98 1.31 
5 R+5 0.74 0.79 0.54 0.94 1.61 1.41 
10 R+lO 1.04 0.75 0.47 0.99 1.75 1.42 
10.25 Re 0.91 0.85 0.53 0.95 1.70 0.95 
15 .25 Re+5 0.99 0.84 0.64 1.14 1.92 1.67 
20.25 Re+l0 0.83 0.85 0.56 0.92 1.91 1.73 
D . hR oxapram wit estnct1on Effi ect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 RI-0.5 1.17 0.44 0.54 1.17 2.59 1.48 
0 RI 0.79 0.32 0.43 1.03 1.50 0.87 
0.5 RI+0.5 0.81 0.44 0.33 0.78 1.56 0.96 
1 Rl+l 0.83 0.38 0.35 0.78 1.74 1.12 
2 Rl+2 0.89 0.42 0.45 0.81 1.89 1.17 
5 RI+5 0.91 0.35 0.47 0.87 2.16 1.19 
10 RI+l0 1.00 0.35 0.45 0.90 2.42 1.24 
10.25 Re 1.03 0.35 0.51 1.04 2.36 1.12 
15.25 Re+5 1.05 0.53 0.47 1.12 2.37 1.18 
20.25 Re+l0 1.04 0.55 0.52 1.11 2.35 1.13 
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Table B3 : Expiration time (s) 
D Effi oxapram ect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 I- 0.5 4.44 6.39 1.02 2.05 5.53 10.81 
0 I 0.97 1.08 0.86 2.28 1.10 1.75 
0.5 l+0.5 1.32 1.96 0.59 1.74 1.33 2.48 
1 I+l 1.32 1.55 0.57 1.52 1.68 5.14 
2 l+2 0.97 1.23 0.53 1.27 1.95 5.77 
5 l+5 0.75 1.27 0.53 2.01 3.56 9.31 
10 l+10 1.72 3.78 0.61 2.35 4.26 9.92 
15 l+15 3.11 5.29 0.41 2.91 4.83 9.38 
Restriction Effect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 R-0.5 7.43 5.13 0.96 5.94 5.39 8.44 
0 R 4.44 3.92 0.55 5.62 5.02 2.59 
5 R+5 7.49 3.85 1.31 3.51 5.55 6.85 
10 R+l0 6.91 3.64 1.41 3.77 6.60 3.88 
10.25 Re 8.20 1.95 0.93 5.68 5.72 1.43 
15 .25 Re+5 5.09 1.93 1.15 5.30 5.25 5.71 
20.25 Re+l0 5.46 1.68 0.86 4.94 5.59 9.27 
D . hR oxapram wit estnct1on Effi ect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0 .5 Rl-0 .5 3.61 1.82 1.62 1.16 3.91 11 .90 
0 RI 0.77 0.46 0.51 0.62 1.43 1.38 
0.5 RI+0.5 1.37 1.53 1.46 0.81 1.97 1.75 
1 RI+l 1.62 1.33 1.23 0.72 1.76 2.14 
2 RI+2 1.92 1.44 1.39 0.75 2.03 2.74 
5 Rl+5 1.66 0.61 0.48 0.83 2.00 5.38 
10 RI+l0 2.00 0.43 0.51 0.88 3.01 3.55 
10.25 Re 2.99 0.52 0.68 1.04 3.04 6.18 
15 .25 Re+5 2.45 1.11 1.24 1.20 3.19 6.26 
20.25 Re+l0 2.59 3.24 3.22 1.26 3.48 2.70 
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Table B4: Ratio of inspiration time I expiration time 
D Effi oxapram ect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 I- 0.5 0.34 0.22 1.20 0.49 0.47 0.16 
0 I 0.74 0.71 0.99 0.39 0.99 0.62 
0.5 l+0.5 0.57 0.38 0.71 0.49 1.11 0.48 
1 I+l 0.57 0.39 0.75 0.76 0.84 0.26 
2 l+2 0.72 0.46 0.81 1.03 0.86 0.25 
5 l+5 0.97 0.42 0.85 0.76 0.70 0.14 
10 l+10 0.60 0.29 0.85 0.70 0.70 0.14 
15 l+15 0.43 0.22 1.95 0.56 0.57 0.16 
Restriction Effect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog5 Dog6 
-0.5 R-0.5 0.13 0.16 0.65 0.19 0.38 0.25 
0 R 0.23 0.14 0.78 0.23 0.39 0.51 
5 R+5 0.10 0.21 0.41 0.27 0.29 0.21 
10 R+l0 0.15 0.21 0.33 0.26 0.27 0.37 
10.25 Re 0.11 0.44 0.57 0.17 0.30 0.66 
15.25 Re+5 0.19 0.44 0.56 0.22 0.37 0.29 
20.25 Re+l0 0.15 0.51 0.65 0.19 0.34 0.19 
D . hR oxapram wit estnct1on Effi t ec 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog5 Dog6 
-0.5 RI-0.5 0.32 0.24 0.33 1.01 0.66 0.12 
0 RI 1.03 0.70 0.84 1.66 1.05 0.63 
0.5 Rl+0.5 0.59 0.29 0.23 0.96 0.79 0.55 
1 RI+l 0.51 0.29 0.28 1.08 0.99 0.52 
2 RI+2 0.46 0.29 0.32 1.08 0.93 0.43 
5 RI+5 0.55 0.57 0.98 1.05 1.08 0.22 
10 Rl+lO 0.50 0.81 0.88 1.02 0.80 0.35 
10.25 Re 0.34 0.67 0.75 1.00 0.78 0.18 
15.25 Re+5 0.43 0.48 0.38 0.93 0.74 0.19 
20.25 Re+l0 0.40 0.17 0.16 0.88 0.68 0.42 
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Table BS : Airway pressure (mmHg) 
D Effi t oxapram ec 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog5 Dog6 
-0.5 I- 0.5 11 .72 4.11 9.87 8.75 5.74 1.48 
0 I 7.88 1.28 6.09 4.89 7.49 10.49 
0.5 I+0.5 9.63 1.62 8.99 7.92 15.45 7.48 
1 I+l 9.03 2.47 10.35 16.41 6.25 7.08 
2 1+2 13 .34 2.55 9.16 5.97 3.41 5.97 
5 1+5 6.94 1.94 8.99 5.40 3.15 6.98 
10 1+10 3.37 0.78 5.39 4.89 2.94 8.08 
15 1+15 7.55 1.03 5.13 4.11 2.74 9.38 
Restriction Effect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 R-0.5 12.87 7.28 9.94 8.79 4.60 0.17 
0 R 5.66 1.13 3.42 4.78 3.15 8.43 
5 R+S 6.60 1.37 4.60 3.86 3.31 6.17 
10 R+l0 6.00 1.26 5.13 3.86 3.36 6.07 
10.25 Re 5.52 1.46 6.09 4.06 3.56 3.06 
15.25 Re+S 5.86 1.42 5.22 5.04 3.41 4.67 
20.25 Re+lO 5.32 1.38 6.09 4.94 3.51 7.58 
D . hR oxapram wit estnct1on Effi ect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 RI-0.5 4.18 1.13 4.60 4.11 4.18 8.63 
0 RI 6.33 1.32 6.01 5.71 5.89 10.54 
0.5 RI+0.5 8.96 1.12 8.02 5.71 6.30 9.99 
1 RI+l 7.14 1.12 8.20 5.97 5.68 7.68 
2 Rl+2 8.02 1.27 7.19 4.99 5.37 6.62 
5 Rl+S 5.05 1.22 5.79 4.58 3.93 6.67 
10 RI+l0 5.52 1.22 6.80 4.01 3.51 7.03 
10.25 Re 4.18 0.75 6.09 4.37 3.62 7.28 
15.25 Re+S 4.99 0.89 6.05 4.58 3.67 7.43 
20.25 Re+l0 5.52 1.10 7.41 4.42 3.77 8.23 
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Table B6: Esophageal pressure (mrnHg) 
D Effi t oxapram ec 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 I- 0.5 15.19 2.30 7.80 10.85 5.60 8.35 
0 I 20.32 2.87 11.79 11.29 11.51 11.59 
0.5 l+0.5 39.06 3.30 19.24 7.74 7.43 10.51 
1 l+1 39.06 3.30 19.24 7.74 7.43 10.51 
2 l+2 46.15 3.23 17.05 7.35 5.86 9.23 
5 l+5 25 .99 2.77 15 .69 6.31 4.99 9.62 
10 l+10 3.81 1.82 9.79 6.56 4.63 11.05 
15 l+15 5.08 2.18 9.79 6.51 4.84 9.82 
Restriction Effect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog5 Dog6 
-0.5 R-0.5 6.09 2.46 7.55 5.67 5.04 9.82 
0 R 6.09 2.19 6.43 4.98 4.79 9.23 
5 R+5 6.35 2.47 9.65 5.37 5.24 6.78 
10 R+l0 7.52 2.88 10.57 5.97 5.40 6.48 
10.25 Re 7.83 2.78 10.18 6.56 5.45 3.88 
15.25 Re+5 7.36 2.69 10.13 7.69 5.45 5.30 
20.25 Re+l0 6.30 2.89 9.94 7.35 5.45 8.69 
D 'th R t t Effi t oxapram w1 es nc 10n ec 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog5 Dog6 
-0.5 RI-0.5 4.08 2.30 10.67 7.05 5.04 9.87 
0 RI 6.62 2.79 12.96 7.84 7.08 10.80 
0.5 RI+0.5 5.29 2.69 14.52 9.42 7.74 9.52 
1 RI+l 5.40 2.59 16.03 8.93 8.15 8.10 
2 RI+2 5.03 2.54 14.27 7.79 6.42 7.32 
5 RI+5 4.60 3.64 14.37 7.45 4.53 7.32 
10 RI+l0 4.76 3.08 13.45 6.95 5.45 7.95 
10.25 Re 4.92 1.38 13 .50 7.54 4.68 8.35 
15 .25 Re+5 5.19 1.82 13 .20 7.54 4.53 8.74 
20.25 Re+l0 4.66 2.50 14.42 7.40 4.68 9.38 
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Table B7: Specific tidal volume (mL/Kg) 
D Effi t oxapram ec 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 I- 0.5 17.9 15.9 6.6 15.1 11.4 15.3 
0 I 20.2 17.5 9.4 14.5 19.6 22.0 
0.5 l+0.5 23.4 20.0 9.9 9.5 17.5 22.9 
1 I+l 22.2 18.2 10.5 9.8 13.1 21.8 
2 l+2 16.4 15.2 8.9 9.1 10.5 20.1 
5 l+5 10.4 12.6 7.2 8.4 10.0 21.6 
10 l+10 6.5 12.7 5.8 8.6 10.0 20.9 
15 l+15 18.3 16.5 6.7 8.3 10.5 22.8 
Restriction Effect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 R-0.5 11.7 19.2 5.4 11.0 10.6 20.6 
0 R 12.8 13.1 2.9 9.1 8.9 13 .8 
5 R+5 12.4 16.5 5.7 6.9 9.8 12.0 
10 R+lO 14.5 17.2 6.6 6.8 10.9 11.1 
10.25 Re 12.4 16.3 6.3 7.9 10.8 6.0 
15 .25 Re+5 13.1 15.9 6.4 9.3 10.6 8.9 
20.25 Re+l0 11.5 15 .3 6.1 9.5 10.7 16.8 
D . th R t t Effi t oxapram w1 es nc 10n ec 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 RI-0 .5 6.6 11.0 4.9 6.0 9.4 19.9 
0 RI 7.2 9.9 6.3 8.0 13 .5 17.1 
0.5 RI+0.5 7.3 10.8 6.9 7.7 12.6 14.9 
1 RI+l 7.1 11.1 6.8 7.6 12.0 12.9 
2 RI+2 5.5 9.4 6.4 6.6 11.0 11.9 
5 RI+5 5.4 9.1 6.1 5.8 8.3 12.9 
10 RI+l0 7.1 10.9 5.9 5.7 8.4 13.5 
10.25 Re 7.3 5.1 5.6 6.9 9.0 13 .7 
15.25 Re+5 7.4 7.4 6.2 7.7 9.1 15.1 
20.25 Re+l0 7.6 10.6 6.6 7.7 9.0 15.8 
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Table B8: Specific minute volume (mL/Kg min) 
D Effi oxapram ect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog5 Dog6 
-0.5 I- 0.5 179 111 172 287 80 61 
0 I 708 560 329 262 529 462 
0.5 I+0.5 655 440 586 219 367 366 
1 I+l 643 492 631 215 249 196 
2 I+2 574 502 554 210 168 161 
5 I+5 418 417 440 135 90 108 
10 I+lO 137 152 309 129 80 105 
15 !+15 238 148 326 108 74 114 
Restriction Effect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog5 Dog6 
-0.5 R-0.5 82 192 204 88 85 103 
0 R 141 170 174 73 71 207 
5 R+5 87 198 183 89 78 84 
10 R+lO 101 223 204 82 76 122 
10.25 Re 74 342 257 71 86 150 
15 .25 Re+5 118 335 212 84 85 71 
20.25 Re+lO 103 352 257 95 86 84 
D ·th R t t Effi t oxapram w1 es nc 10n ec 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog5 Dog6 
-0.5 RI-0.5 79 285 133 150 84 80 
0 RI 274 749 396 289 270 444 
0.5 RI+0.5 196 324 228 286 215 327 
1 RI+l 171 378 260 304 204 233 
2 RI+2 115 302 204 249 164 179 
5 RI+5 123 565 379 201 116 116 
10 RI+lO 141 830 367 187 92 162 
10.25 Re 102 355 279 193 99 109 
15 .25 Re+5 126 265 218 192 91 121 
20.25 Re+lO 122 159 106 193 90 237 
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Table B9: Compliance work (mmHg L) 
D Effi t oxapram ec 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 I- 0.5 4.69 0.50 1.01 3.12 1.31 2.33 
0 I 7.10 0.68 2.17 3.13 4.62 4.64 
0.5 l+0.5 15 .78 0.90 3.74 1.41 2.66 4.37 
1 I+l 14.95 0.82 3.96 1.44 2.00 4.17 
2 l+2 13 .07 0.67 2.98 1.28 1.26 3.38 
5 l+5 4.69 0.48 2.21 1.02 1.03 3.78 
10 l+10 0.43 0.31 1.12 1.07 0.95 4.21 
15 l+15 1.61 0.49 1.27 1.03 1.04 4.08 
Restriction Effect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 R-0.5 1.23 0.64 0.79 1.19 1.09 3.69 
0 R 1.35 0.39 0.36 0.87 0.88 2.32 
5 R+5 1.36 0.55 1.08 0.70 1.05 1.48 
10 R+l0 1.88 0.67 1.36 0.78 1.21 1.31 
10.25 Re 1.68 0.62 1.25 0.99 1.20 0.42 
15.25 Re+5 1.67 0.58 1.27 1.37 1.19 0.86 
20.25 Re+l0 1.25 0.60 1.19 1.33 1.19 2.66 
D "th R t t Effi t oxapram w1 es nc 10n ec 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog5 Dog6 
-0.5 RI-0 .5 0.46 0.34 1.02 0.81 0.97 3.57 
0 RI 0.82 0.37 1.59 1.20 1.96 3.36 
0.5 RI+0.5 0.66 0.40 1.96 1.39 2.00 2.57 
1 RI+l 0.66 0.39 2.14 1.29 2.00 1.90 
2 RI+2 0.48 0.33 1.78 0.97 1.44 1.59 
5 RI+5 0.43 0.45 1.72 0.82 0.77 1.72 
10 RI+l0 0.58 0.46 1.56 0.75 0.94 1.95 
10.25 Re 0.62 0.10 1.47 0.99 0.86 2.07 
15 .25 Re+5 0.67 0.18 1.61 1.10 0.84 2.40 
20.25 Re+l0 0.61 0.36 1.87 1.09 0.87 2.70 
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Table B10: Heart rate (BPM) 
D Effi t oxapram ec 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog5 Dog6 
-0.5 I- 0.5 156 156 144 138 132 144 
0 I 174 162 120 144 150 168 
0.5 l+0.5 198 174 114 150 162 174 
1 I+l 198 198 120 156 162 168 
2 l+2 186 204 138 156 180 168 
5 l+5 186 192 144 156 174 186 
10 l+10 168 174 150 156 162 180 
15 l+15 168 162 144 150 162 174 
Restriction Effect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 R-0.5 144 186 156 126 162 168 
0 R 138 198 156 132 162 192 
5 R+5 138 180 150 126 162 162 
10 R+lO 144 180 156 120 150 168 
10.25 Re 144 174 156 114 150 180 
15.25 Re+5 150 186 156 120 156 180 
20.25 Re+l0 144 162 150 120 156 168 
D 'th R t . f Effi t oxapram w1 es nc 10n ec 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 RI-0.5 156 174 126 156 156 156 
0 RI 156 162 120 162 162 168 
0.5 RI+0.5 150 132 120 162 156 168 
1 RI+l 150 138 120 162 162 174 
2 RI+2 144 150 126 168 162 180 
5 Rl+5 156 174 120 162 168 180 
10 RI+l0 156 180 126 168 162 174 
10.25 Re 138 210 120 162 162 180 
15.25 Re+5 150 168 114 168 162 180 
20.25 Re+l0 150 150 126 168 168 174 
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Table B 11 : Systolic pressure (mmHg) 
D Effi t oxapram ec 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog5 Dog6 
-0.5 I- 0.5 * * 133 150 165 213 
0 I * * 146 183 194 237 
0.5 I+0.5 * * 149 164 208 246 
1 I+l * * 156 166 * 238 
2 1+2 * * 150 170 * 226 
5 1+5 * * 160 169 * 221 
10 1+10 * * 158 173 170 230 
15 1+15 * * 156 172 169 236 
Restriction Effect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 R-0.5 * * 140 155 172 228 
0 R * * 146 153 180 226 
5 R+S * * 156 157 168 225 
10 R+lO * * 142 160 171 220 
10.25 Re * * 120 153 169 181 
15.25 Re+5 * * 119 154 168 195 
20.25 Re+l0 * * 118 153 167 209 
D . hR estnct1on oxapram wit Effi ect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 RI-0.5 * * 148 179 166 211 
0 RI * * 172 205 208 233 
0.5 RI+0.5 * * 186 201 201 * 
1 RI+l * * 176 198 202 231 
2 RI+2 * * 165 192 177 225 
5 RI+5 * * 145 193 173 222 
10 RI+l0 * * 125 195 174 219 
10.25 Re * * 165 190 174 221 
15.25 Re+S * * 156 190 174 222 
20.25 Re+l0 * * 136 190 173 * 
*Data not collected 
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Table B 12: Diastolic pressure (mmHg) 
D Efli t oxapram ec 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog5 Dog6 
-0.5 I- 0.5 * * 117 105 117 128 
0 I * * 102 125 129 141 
0.5 1+0.5 * * 109 116 103 129 
1 l+1 * * 106 122 * 148 
2 1+2 * * 106 125 * 143 
5 l+5 * * 112 124 * 142 
10 l+10 * * 115 125 128 146 
15 l+15 * * 118 122 127 142 
Restriction Effect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog5 Dog6 
-0.5 R-0.5 * * 118 109 127 142 
0 R * * 122 112 128 146 
5 R+5 * * 136 113 128 142 
10 R+lO * * 122 114 125 140 
10.25 Re * * 107 101 125 118 
15.25 Re+5 * * 106 104 125 130 
20.25 Re+l0 * * 95 101 125 136 
D . hR oxapram wit estnct1on Efli ect 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
-0.5 RI-0.5 * * 113 129 126 133 
0 RI * * 126 145 147 143 
0.5 RI+0.5 * * 133 141 115 * 
1 Rl+l * * 131 143 137 152 
2 RI+2 * * 123 140 133 150 
5 RI+5 * * 107 140 130 146 
10 RI+l0 * * 88 140 130 143 
10.25 Re * * 107 135 130 145 
15 .25 Re+5 * * 102 136 130 145 
20.25 Re+l0 * * 93 134 129 * 
*Data not collected 
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Table B 13: Arterial blood oxygen partial pressure (mmHg) 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog5 Dog6 
0 Base 1 93 .9 91.7 91.5 93.4 95 .8 95 .6 
10 Base 2 94.6 95 .2 92.6 96.1 97.2 99.2 
0.25 1+0.25 97.1 96.2 96.7 98 .5 99.2 98.7 
15 l+15 93 .9 95.2 93.8 96.2 96.9 96.8 
0.25 R+0.25 97.4 94.0 93.6 97.1 97.0 97.4 
10 R+l0 95 .0 91.1 93.2 96.3 95.9 95.4 
20 Re+l0 * 92.6 * 96.0 97.3 88 .2 
0.25 RI+0.25 97.2 91.1 96.4 98.6 98.8 98.6 
10 RI+l0 96.2 94.0 93 .5 97 .3 97.6 95.4 
20 Re+l0 95.6 92.4 90.7 96.4 96.1 95.2 
Table B14: Arterial blood carbon dioxide partial pressure (mmHg) 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
0 Base 1 43 .6 46.0 41.3 42 .5 37.8 37.6 
10 Base 2 48.8 37.7 37.5 42 .7 44.8 38.7 
0.25 1+0.25 39.6 35 .8 25 .0 34.4 33.4 30.6 
15 l+15 43 .3 40.0 29.9 37.3 42.2 31.8 
0.25 R+0.25 42.1 35.9 34.7 41.4 41.9 33 .7 
10 R+l0 46.9 39.7 34.5 41.2 40.4 34.8 
20 Re+l0 * 37.4 * 38.9 42.3 39.2 
0.25 RI+0.25 42.1 36.1 23 .1 34.5 32.8 28.4 
10 RI+lO 46.6 34.2 26.4 37.3 37.8 32.5 
20 Re+l0 45 .3 34.3 26.0 36.4 38.8 34.1 
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Table B 15 : Arterial blood pH 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog5 Dog6 
0 Base 1 7.298 7.306 7.328 7.286 7.335 7.391 
10 Base 2 7.315 7.385 7.357 7.327 7.350 7.403 
0.25 I+0.25 7.357 7.362 7.456 7.397 7.440 7.453 
15 l+15 7.333 7.329 7.443 7.348 7.360 7.444 
0.25 R+0.25 7.349 7.355 7.368 7.334 7.365 7.428 
10 R+l0 7.309 7.334 7.357 7.327 7.361 7.419 
20 Re+l0 * 7.354 * 7.334 7.359 7.383 
0.25 Rl+0.25 7.356 7.351 7.499 7.382 7.421 7.469 
10 RI+l0 7.334 7.392 7.479 7.367 7.395 7.438 
20 Re+l0 7.342 7.386 7.464 7.355 7.373 7.415 
Table B16: Arterial blood hematocrit (percent ofred blood cells in blood) 
Time Event Dog 1 Dog2 Dog3 Dog4 Dog 5 Dog6 
0 Base 1 41.3 42.3 43.0 37.8 34.7 37.3 
10 Base 2 44.0 36.7 43 .0 39.0 42.3 37.0 
0.25 I+0.25 45 .3 43.5 49.8 40 .5 43.7 36.0 
15 l+15 49.5 42.7 49.8 44.0 42.7 42.0 
0.25 R+0.25 42.3 47.3 46.0 37.5 45.0 42.3 
10 R+l0 34.0 44.8 47.5 41.3 44.3 41.3 
20 Re+I0 * 44.0 * 40.5 45.8 45 .8 
0.25 RI+0.25 50.3 42.0 53 .0 44.3 46.3 43 .5 
10 Rl+I0 49.3 37.3 52.7 47.0 46.8 45.3 
20 Re+I0 46.7 36.0 52.8 48 .3 46.7 46.8 
60 
APPENDIX C: DATA SET ANALYSIS 
61 
Table C 1: Respiration rate (BPM) 
D Effi t oxapram ec 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV A, , o Sdev. CV Avg. Sdev. CV 
-0.5 I- 0.5 18.3 8.0 44 6.0 1.7 29 12 9 70 
0 I 29.3 9.8 33 26.7 5.5 21 28 7 26 
0.5 l+0.5 36.7 19.5 53 19.7 3.2 16 28 16 55 
1 I+l 37.0 20.2 55 18.3 9.0 49 28 17 63 
2 l+2 40.0 20.0 50 19.0 12.8 67 30 19 64 
5 l+5 39.0 22.5 58 15 .7 15.1 97 27 21 78 
10 l+10 29.7 20.4 69 8.3 3.5 42 19 18 92 
15 1+15 25.0 20.8 83 7.0 2.0 29 16 16 103 
Restriction Effect 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 R-0.5 17.7 17.6 100 7.7 2.5 33 13 13 99 
0 R 26.7 29.8 112 12.0 3.6 30 19 21 107 
5 R+5 17.3 13 .1 75 9.0 2.6 29 13 10 73 
10 R+l0 16.7 12.7 76 10.3 3.1 30 14 9 66 
10.25 Re 18.7 19.4 104 18.0 8.9 49 18 14 74 
15 .25 Re+5 17.0 13.9 82 12.3 7.5 61 15 10 70 
20.25 Re+l0 20.3 18.8 92 12.0 9.6 80 16 14 87 
D "th R t . ( Effi t oxapram w1 es nc 10n ec 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 RI-0.5 21.3 8.1 38 13 .0 11.5 89 17 10 58 
0 RI 45.7 15.0 33 40.7 30.7 76 43 22 51 
0.5 RI+0.5 32.3 5.0 16 23.0 6.6 29 28 7 26 
1 Rl+l 34.0 8.7 26 23 .0 9.5 41 29 10 36 
2 Rl+2 30.3 8.6 28 20.7 9.8 47 26 10 38 
5 RI+5 40.0 20.0 50 28 .3 29.3 103 34 23 68 
10 RI+l0 38.3 21.5 56 33 .0 37.2 113 36 27 77 
10.25 Re 30.7 18.1 59 29.3 34.4 117 30 25 82 
15.25 Re+5 25 .7 9.0 35 18.0 15 .6 87 22 12 56 
20.25 Re+l0 19.0 5.2 27 13.3 2.9 22 16 5 30 
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Table C2: Inspiration time (s) 
D Effi t oxapram ec 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 I- 0.5 1.25 0.26 21 1.92 0.60 31 1.58 0.55 35 
0 I 0.82 0.09 11 0.98 0.18 19 0.90 0.16 18 
0.5 l+0.5 0.67 0.23 33 1.14 0.36 32 0.91 0.37 41 
1 l+1 0.78 0.36 46 1.13 0.45 40 0.95 0.41 43 
2 l+2 0.81 0.45 55 1.23 0.58 47 1.02 0.52 51 
5 l+5 0.90 0.56 62 1.45 0.98 68 1.17 0.78 67 
10 l+10 1.06 0.56 53 1.81 1.03 57 1.44 0.85 59 
15 l+15 1.26 0.43 34 1.79 0.83 46 1.52 0.66 43 
Restriction Effect 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 R-0.5 0.91 0.25 28 1.66 0.74 45 1.28 0.65 51 
0 R 0.91 0.44 48 1.27 0.73 57 1.09 0.57 52 
5 R+5 0.74 0.20 27 1.27 0.43 34 1.00 0.42 42 
10 R+l0 0.83 0.32 38 1.31 0.51 39 1.07 0.46 43 
10.25 Re 0.80 0.23 29 1.17 0.46 40 0.98 0.39 40 
15.25 Re+5 0.92 0.26 28 1.48 0.57 38 1.20 0.49 41 
20.25 Re+l0 0.77 0.19 24 1.50 0.57 38 1.13 0.55 49 
D 'th R t t Effi t oxapram w1 es nc 10n ec 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 RI-0 .5 0.96 0.36 38 1.50 1.08 72 1.23 0.78 63 
0 RI 0.75 0.30 40 0.90 0.59 66 0.82 0.43 52 
0.5 Rl+0.5 0.64 0.27 42 0.99 0.56 57 0.81 0.43 53 
1 Rl+l 0.65 0.26 40 1.08 0.68 63 0.87 0.52 60 
2 Rl+2 0.72 0.23 33 1.16 0.74 63 0.94 0.54 57 
5 R1+5 0.75 0.24 32 1.23 0.91 73 0.99 0.65 66 
10 RI+l0 0.78 0.29 37 1.34 1.04 78 1.06 0.75 71 
10.25 Re 0.86 0.30 35 1.28 1.01 79 1.07 0.71 66 
15 .25 Re+5 0.88 0.36 41 1.36 0.93 69 1.12 0.69 62 
20.25 Re+l0 0.89 0.32 36 1.34 0.92 68 1.12 0.66 59 
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Table C3 : Expiration time ( s) 
D Effi oxapram ect 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 I- 0.5 2.50 1.80 70 7.58 2.83 37 5.04 3.49 69 
0 I 1.37 0.79 58 1.31 0.38 29 1.34 0.56 42 
0.5 1+0.5 1.22 0.58 48 1.92 0.58 30 1.57 0.65 41 
1 l+l 1.14 0.50 44 2.79 2.04 73 1.96 1.61 82 
2 l+2 0.92 0.37 40 2.98 2.44 82 1.95 1.93 99 
5 l+5 1.10 0.80 73 4.71 4.14 88 2.91 3.32 114 
10 l+10 1.56 0.88 56 5.99 3.41 57 3.77 3.29 87 
15 l+15 2.14 1.50 70 6.50 2.50 39 4.32 3.02 70 
Restriction Effect 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 R-0.5 4.78 3.39 71 6.32 1.84 29 5.55 2.58 46 
0 R 3.54 2.65 75 3.84 1.22 32 3.69 1.85 50 
5 R+5 4.10 3.13 76 5.42 1.50 28 4.76 2.31 49 
10 R+lO 4.03 2.76 68 4.71 1.64 35 4.37 2.06 47 
10.25 Re 4.94 3.69 75 3.03 2.34 77 3.99 2.95 74 
15 .25 Re+5 3.85 2.34 61 4.30 2.06 48 4.07 1.99 49 
20.25 Re+l0 3.75 2.52 67 5.51 3.80 69 4.63 3.04 66 
D 'th R t . f Effi t oxapram w1 es nc 10n ec 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 RI-0.5 2.13 1.30 61 5.88 5.32 91 4.00 4.03 101 
0 RI 0.63 0.13 21 1.09 0.55 50 0.86 0.43 50 
0.5 RI+0.5 1.21 0.35 29 1.75 0.22 13 1.48 0.39 26 
1 RI+l 1.19 0.45 38 1.74 0.41 23 1.47 0.49 33 
2 RI+2 1.35 0.59 43 2.07 0.65 31 1.71 0.68 40 
5 RI+5 0.99 0.61 61 2.66 2.45 92 1.83 1.84 101 
10 RI+l0 1.13 0.78 69 2.33 1.67 72 1.73 1.34 77 
10.25 Re 1.57 1.24 79 3.25 2.84 87 2.41 2.16 90 
15.25 Re+5 1.63 0.71 44 3.52 2.59 74 2.58 1.99 77 
20.25 Re+l0 2.36 1.00 42 3.14 0.40 13 2.75 0.81 29 
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Table C4: Ratio of inspiration time/ expiration time 
D E:ffi t oxapram ec 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV A,1a Sdev. CV Avg. Sdev. CV 
-0.5 I- 0.5 0.68 0.45 67 0.28 0.16 57 0.48 0.37 78 
0 I 0.71 0.30 43 0.77 0.19 25 0.74 0.23 31 
0.5 I+0.5 0.59 0.11 19 0.66 0.39 60 0.62 0.26 42 
1 I+l 0.69 0.11 16 0.50 0.30 60 0.60 0.23 38 
2 I+2 0.85 0.16 19 0.52 0.31 59 0.69 0.28 41 
5 I+5 0.86 0.11 12 0.42 0.28 66 0.64 0.31 48 
10 I+lO 0.72 0.13 18 0.37 0.29 78 0.55 0.28 50 
15 I+15 0.98 0.84 86 0.31 0.22 70 0.65 0.66 102 
Restriction Effect 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 R-0 .5 0.32 0.28 88 0.26 0.11 43 0.29 0.19 67 
0 R 0.41 0.32 77 0.35 0.19 55 0.38 0.24 63 
5 R+5 0.26 0.16 60 0.23 0.05 21 0.25 0.10 43 
10 R+l0 0.25 0.09 37 0.28 0.08 29 0.26 0.08 30 
10.25 Re 0.28 0.25 89 0.47 0.19 40 0.37 0.22 59 
15 .25 Re+5 0.32 0.20 63 0.36 0.07 20 0.34 0.14 40 
20.25 Re+l0 0.33 0.28 85 0.34 0.16 46 0.34 0.20 60 
D ·th R t . f Effi t oxapram w1 es nc 10n ec 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 RI-0 .5 0.56 0.39 71 0.34 0.28 83 0.45 0.33 73 
0 RI 1.18 0.43 36 0.79 0.23 28 0.98 0.37 38 
0.5 RI+0.5 0.59 0.37 62 0.54 0.25 46 0.57 0.28 50 
1 RI+l 0.63 0.41 66 0.60 0.36 60 0.61 0.35 56 
2 RI+2 0.62 0.40 65 0.55 0.34 61 0.59 0.33 57 
5 RI+5 0.86 0.27 32 0.62 0.43 69 0.74 0.35 47 
10 RI+l0 0.80 0.27 34 0.66 0.27 40 0.73 0.25 35 
10.25 Re 0.70 0.33 47 0.54 0.32 59 0.62 0.30 49 
15 .25 Re+5 0.58 0.31 53 0.47 0.28 59 0.52 0.27 51 
20.25 Re+l0 0.48 0.37 76 0.42 0.25 60 12.70 19.03 150 
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Table CS: Airway pressure (mmHg) 
D Effi t oxapram ec 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 I- 0.5 10.11 1.50 15 3.78 2.15 57 6.95 3.85 55 
0 I 6.29 1.50 24 6.42 4.70 73 6.35 3.12 49 
0.5 l+0.5 8.85 0.86 10 8.18 6.94 85 8.51 4.44 52 
1 I+l 11 .93 3.94 33 5.27 2.46 47 8.60 4.68 54 
2 l+2 9.49 3.70 39 3.98 1.78 45 6.73 3.98 59 
5 l+5 7.11 1.80 25 4.02 2.63 65 5.57 2.63 47 
10 l+10 4.55 1.05 23 3.93 3.75 95 4.24 2.49 59 
15 l+15 5.60 1.77 32 4.38 4.41 101 4.99 3.08 62 
Restriction Effect 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 R-0.5 10.53 2.10 20 4.02 3.59 89 7.27 4.44 61 
0 R 4.62 1.13 24 4.24 3.77 89 4.43 2.50 56 
5 R+5 5.02 1.42 28 3.62 2.41 67 4.32 1.93 45 
10 R+l0 5.00 1.08 22 3.56 2.41 68 4.28 1.85 43 
10.25 Re 5.22 1.05 20 2.69 1.10 41 3.96 1.69 43 
15 .25 Re+5 5.37 0.43 8 3.17 1.64 52 4.27 1.62 38 
20.25 Re+l0 5.45 0.59 11 4.16 3.15 76 4.80 2.15 45 
D "th R t t Effi t oxapram w1 es nc 10n ec 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 RI-0 .5 4.30 0.27 6 4.65 3.77 81 4.47 2.40 54 
0 RI 6.02 0.31 5 5.92 4.61 78 5.97 2.92 49 
0.5 RI+0.5 7.56 1.67 22 5.80 4.46 77 6.68 3.16 47 
1 RI+l 7.10 1.12 16 4.83 3.36 70 5.97 2.56 43 
2 RI+2 6.73 1.57 23 4.42 2.80 63 5.58 2.39 43 
5 RI+5 5.14 0.61 12 3.94 2.73 69 4.54 1.88 41 
10 Rl+l0 5.44 1.40 26 3.92 2.93 75 4.68 2.21 47 
10.25 Re 4.88 1.05 22 3.88 3.27 84 4.38 2.24 51 
15.25 Re+5 5.21 0.76 15 4.00 3.28 82 4.60 2.23 48 
20.25 Re+l0 5.78 1.51 26 4.37 3.60 82 5.08 2.59 51 
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Table C6: Esophageal pressure (mmHg) 
D Effi t oxapram ec 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 I- 0.5 11.28 3.71 33 5.42 3.03 56 8.35 4.41 53 
0 I 14.47 5.08 35 8.66 5.01 58 11.56 5.52 48 
0.5 l+0.5 22.01 15 .84 72 7.08 3.62 51 14.55 13 .13 90 
1 I+l 22.01 15.84 72 7.08 3.62 51 14.55 13 .13 90 
2 l+2 23 .52 20.19 86 6.11 3.01 49 14.81 16.05 108 
5 l+5 16.00 9.84 62 5.79 3.49 60 10.89 8.65 79 
10 l+10 6.72 2.99 45 5.83 4.73 81 6.28 3.57 57 
15 l+15 7.13 2.41 34 5.61 3.88 69 6.37 3.01 47 
Restriction Effect 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 R-0.5 6.44 0.99 15 5.77 3.73 65 6.10 2.47 40 
0 R 5.83 0.76 13 5.40 3.56 66 5.62 2.32 41 
5 R+5 7.12 2.24 31 4.83 2.18 45 5.98 2.34 39 
10 R+l0 8.02 2.34 29 4.92 1.85 38 6.47 2.54 39 
10.25 Re 8.19 1.84 22 4.04 1.34 33 6.11 2.69 44 
15 .25 Re+5 8.39 1.51 18 4.48 1.55 35 6.44 2.54 39 
20.25 Re+l0 7.86 1.87 24 5.68 2.91 51 6.77 2.49 37 
D . h R . f Effi t oxapram wit estnc 10n ec 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 RI-0 .5 7.27 3.30 45 5.74 3.83 67 6.50 3.31 51 
0 RI 9.14 3.36 37 6.89 4.01 58 8.01 3.53 44 
0.5 RI+0.5 9.74 4.62 47 6.65 3.54 53 8.20 4.05 49 
1 RI+l 10.12 5.41 53 6.28 3.20 51 8.20 4.50 55 
2 RI+2 9.03 4.74 53 5.43 2.54 47 7.23 3.94 54 
5 RI+5 8.81 5.02 57 5.16 1.92 37 6.98 3.94 56 
10 RI+lO 8.39 4.52 54 5.49 2.44 44 6.94 3.61 52 
10.25 Re 8.65 4.40 51 4.80 3.49 73 6.73 4.13 61 
15 .25 Re+5 8.64 4.12 48 5.03 3.49 69 6.84 3.95 58 
20.25 Re+l0 8.83 5.03 57 5.52 3.52 64 7.17 4.29 60 
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Table C7: Specific tidal volume (mL/Kg) 
D Effi t oxapram ec 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 I- 0.5 13.2 5.8 44 14.2 2.4 17 13 .7 4.0 29 
0 I 14.7 5.4 37 19.7 2.2 11 17.2 4.6 27 
0.5 l+0.5 14.3 7.9 55 20.1 2.7 13 17.2 6.2 36 
1 I+l 14.1 7.0 49 17.7 4.4 25 15.9 5.6 35 
2 l+2 11.5 4.3 37 15.3 4.8 31 13.4 4.6 34 
5 l+5 8.7 1.6 19 14.8 6.1 41 11.7 5.2 44 
10 l+10 7.0 1.4 20 14.5 5.7 39 10.8 5.6 52 
15 l+15 11.1 6.3 57 16.6 6.2 37 13 .9 6.3 46 
Restriction Effect 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 R-0.5 9.4 3.5 37 16.8 5.4 32 13 .1 5.8 44 
0 R 8.3 5.0 61 11.9 2.6 22 10.1 4.1 41 
5 R+5 8.3 3.6 43 12.7 3.4 27 10.5 4.0 38 
10 R+l0 9.3 4.5 48 13 .1 3.6 27 11.2 4.2 37 
10.25 Re 8.9 3.2 36 11.0 5.2 47 9.9 4.0 40 
15.25 Re+5 9.6 3.4 35 11.8 3.7 31 10.7 3.4 31 
20.25 Re+l0 9.0 2.7 30 14.3 3.2 22 11.6 3.9 34 
D . hR oxapram wit estnct1on Effi ect 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 RI-0.5 5.8 0.8 15 13.4 5.7 42 9.6 5.5 57 
0 RI 7.2 0.9 12 13 .5 3.6 27 10.3 4.2 40 
0.5 RI+0.5 7.3 0.4 5 12.8 2.0 16 10.0 3.3 33 
1 RI+l 7.2 0.4 5 12.0 0.9 7 9.6 2.7 28 
2 Rl+2 6.1 0.6 9 10.8 1.2 12 8.5 2.7 32 
5 RI+5 5.7 0.4 7 10.1 2.5 24 7.9 2.9 36 
10 RI+lO 6.2 0.7 12 10.9 2.5 23 8.6 3.1 36 
10.25 Re 6.6 0.9 14 9.3 4.3 46 7.9 3.1 39 
15 .25 Re+5 7.1 0.8 11 10.5 4.1 39 8.8 3.2 36 
20.25 Re+l0 7.3 0.6 8 11.8 3.6 30 9.3 8.2 88 
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Table C8: Specific minute volume (mL/Kg min) 
D Effi t oxapram ec 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 I- 0.5 213 64 30 84 25 30 148 83 56 
0 I 433 241 56 517 50 10 475 162 34 
0.5 l+0.5 487 235 48 391 42 11 439 160 36 
1 I+l 496 244 49 313 158 50 404 209 52 
2 l+2 446 204 46 277 195 70 361 201 56 
5 l+5 331 170 51 205 184 90 268 173 64 
10 l+10 192 102 53 112 37 33 152 81 53 
15 l+15 224 110 49 112 37 33 168 95 57 
Restriction Effect 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 R-0.5 125 69 55 126 57 45 126 57 45 
0 R 129 52 40 150 70 47 139 56 40 
5 R+5 120 55 46 120 67 56 120 55 46 
10 R+l0 129 66 51 141 75 54 135 64 47 
10.25 Re 134 107 79 193 133 69 164 113 69 
15 .25 Re+5 138 66 48 164 148 91 151 104 69 
20.25 Re+l0 152 91 60 174 154 89 163 114 70 
D "th R t . f Effi t oxapram w1 es nc 10n ec 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 RI-0.5 121 37 31 150 117 78 135 79 59 
0 RI 319 66 21 488 242 50 404 184 45 
0.5 RI+0.5 237 45 19 289 64 22 263 57 22 
1 Rl+l 245 68 28 272 93 34 258 74 29 
2 RI+2 189 68 36 215 76 35 202 66 33 
5 RI+5 234 131 56 266 259 97 250 184 74 
10 Rl+l0 232 119 51 361 407 113 297 278 94 
10.25 Re 191 88 46 188 145 77 189 107 57 
15.25 Re+5 179 47 26 159 93 59 169 67 40 
20.25 Re+l0 140 46 33 162 74 45 151 56 37 
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Table C9: Compliance work (mmHg L) 
D Effi oxapram ect 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 I- 0.5 2.94 1.84 63 1.38 0.92 66 2.16 1.56 72 
0 I 4.13 2.61 63 3.31 2.28 69 3.72 2.24 60 
0.5 I+0.5 6.98 7.72 111 2.64 1.74 66 4.81 5.54 115 
1 I+l 6.78 7.18 106 2.33 1.70 73 4.56 5.27 116 
2 I+2 5.78 6.37 110 1.77 1.43 81 3.77 4.68 124 
5 I+5 2.64 1.87 71 1.76 1.77 101 2.20 1.70 77 
10 I+l0 0.87 0.38 44 1.82 2.09 115 1.35 1.44 107 
15 I+l5 1.31 0.29 22 1.87 1.93 103 1.59 1.28 80 
Restriction Effect 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 R-0.5 1.07 0.24 23 1.81 1.64 91 1.44 1.13 78 
0 R 0.86 0.49 58 1.19 1.00 84 1.03 0.73 71 
5 R+5 1.05 0.33 31 1.03 0.46 45 1.04 0.36 35 
10 R+l0 1.34 0.55 41 1.06 0.34 32 1.20 0.44 36 
10.25 Re 1.31 0.35 27 0.75 0.41 54 1.03 0.46 44 
15.25 Re+5 1.44 0.21 14 0.88 0.30 34 1.16 0.38 33 
20.25 Re+ l0 1.25 0.07 6 1.48 1.06 71 1.37 0.68 50 
· D 'th R t . t' Effi t oxapram w1 es nc 10n ec 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 RI-0 .5 0.77 0.28 37 1.63 1.71 105 1.20 1.20 100 
0 RI 1.21 0.38 32 1.90 1.49 79 1.55 1.05 67 
0.5 RI+0.5 1.34 0.65 49 1.66 1.13 68 1.50 0.84 56 
1 RI+l 1.37 0.74 54 1.43 0.90 63 1.40 0.74 53 
2 RI+2 1.08 0.66 61 1.12 0.69 62 1.10 0.60 55 
5 RI+5 0.99 0.66 67 0.98 0.66 67 0.98 0.59 60 
10 RI+l0 0.96 0.52 54 1.11 0.76 68 1.04 0.59 57 
10.25 Re 1.03 0.43 41 1.01 1.00 99 1.02 0.69 67 
15.25 Re+5 1.13 0.47 42 1.14 1.14 100 1.13 0.78 69 
20.25 Re+l0 1.19 0.64 53 1.31 1.23 94 20.95 31.48 150 
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Table Cl0: Heart rate (BPM) 
D Effi oxapram ect 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 I- 0.5 146 9 6 144 12 8 145 9 6 
0 I 146 27 19 160 9 6 153 18 12 
0.5 1+0.5 154 42 27 170 7 4 162 26 16 
1 1+1 158 39 25 176 19 11 167 27 16 
2 l+2 160 24 15 184 18 10 172 21 12 
5 l+5 162 22 13 184 9 5 173 17 10 
10 l+10 158 9 6 172 9 5 165 10 6 
15 l+15 154 12 8 166 7 4 160 10 6 
Restriction Effect 
Time Event ~striction First Doxapram First Both Sets 
. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 R-0.5 142 15 11 172 12 7 157 19 12 
0 R 142 12 9 184 19 10 163 25 15 
5 R+5 138 12 9 168 10 6 153 18 11 
10 R+l0 140 18 13 166 15 9 153 19 12 
10.25 Re 138 22 16 168 16 9 153 22 14 
15.25 Re+5 142 19 14 174 16 9 158 22 14 
20.25 Re+l0 138 16 12 162 6 4 150 15 10 
D . hR oxapram wit estnct1on Effi ect 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 RI-0.5 146 17 12 162 10 6 154 14 9 
0 RI 146 23 16 164 3 2 155 16 10 
0.5 RI+0.5 144 22 15 152 18 12 148 17 11 
1 RI+l 144 22 15 158 18 12 151 18 12 
2 RI+2 146 21 14 164 15 9 155 17 11 
5 RI+5 146 23 16 174 6 3 160 19 12 
10 RI+l0 150 22 14 172 9 5 161 17 11 
10.25 Re 140 21 15 184 24 13 162 29 18 
15.25 Re+5 144 27 19 170 9 5 157 21 13 
20.25 Re+l0 148 21 14 164 12 8 156 16 10 
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Table Cl 1: Systolic pressure (mmHg) 
D Effi t oxapram ec 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV I Avg. Sdev. CV 
-0.5 I- 0.5 142 13 9 189 34 18 165 34 21 
0 I 164 26 16 215 31 14 190 37 20 
0.5 I+0.5 156 11 7 227 27 12 192 44 23 
1 I+l 161 7 4 238 * * 187 45 24 
2 I+2 160 14 9 226 * * 182 39 22 
5 I+5 164 6 4 221 * * 183 33 18 
10 I+l0 165 10 6 200 43 21 182 32 18 
15 1+15 164 11 7 203 47 23 183 36 19 
Restriction Effect 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV A .. ~ Sdev. CV 
-0.5 R-0.5 147 10 7 200 40 20 174 39 22 
0 R 149 5 3 203 32 16 176 36 21 
5 R+5 157 0 0 197 40 20 177 33 18 
10 R+l0 151 13 9 195 35 18 173 34 19 
10.25 Re 136 23 17 175 8 5 156 26 17 
15.25 Re+5 137 25 18 181 19 11 159 32 20 
20.25 Re+l0 135 25 19 188 30 16 162 38 23 
D "th R t . f Effi t oxapram w1 es nc 10n ec 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 RI-0.5 164 21 13 189 32 17 176 26 15 
0 RI 189 24 13 220 17 8 204 25 12 
0.5 RI+0.5 193 11 6 201 * * 196 9 5 
1 RI+l 187 15 8 216 21 10 202 23 11 
2 RI+2 179 19 11 201 34 17 190 26 14 
5 RI+5 169 34 20 197 35 18 183 33 18 
10 RI+l0 160 50 31 197 32 16 178 40 22 
10.25 Re 177 17 10 198 33 17 187 24 13 
15.25 Re+5 173 24 14 198 34 17 186 28 15 
20.25 Re+l0 163 38 24 173 * * 166 28 17 
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Table C12: Diastolic pressure (mmHg) 
D Effi t oxapram ec 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 I- 0.5 111 9 8 123 8 6 117 9 8 
0 I 113 16 14 135 9 6 124 16 13 
0.5 l+0.5 113 5 5 116 18 16 114 11 10 
1 I+l 114 12 10 148 * * 125 21 17 
2 l+2 115 13 11 143 * * 124 18 15 
5 l+5 118 8 7 142 * * 126 15 12 
10 l+10 120 7 6 137 13 9 128 13 10 
15 l+15 120 3 3 135 10 8 127 10 8 
Restriction Effect 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 R-0.5 114 6 6 134 10 8 124 14 11 
0 R 117 7 6 137 12 9 127 14 11 
5 R+5 124 16 13 135 10 8 130 13 10 
10 R+l0 118 6 5 133 10 8 125 11 8 
10.25 Re 104 4 4 122 5 4 113 11 10 
15.25 Re+5 105 1 1 127 3 3 116 13 11 
20.25 Re+l0 98 4 4 130 8 6 114 19 17 
D 'th R t t Effi t oxapram w1 es nc 10n ec 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
-0.5 RI-0 .5 121 12 10 129 5 4 125 9 7 
0 RI 136 14 10 145 3 2 140 10 7 
0.5 Rl+0.5 137 6 4 115 * * 130 13 10 
1 RI+l 137 8 6 144 10 7 141 9 6 
2 RI+2 131 12 9 142 12 9 136 12 9 
5 RI+5 123 23 19 138 11 8 130 17 13 
10 RI+l0 114 37 32 136 9 6 125 25 20 
10.25 Re 121 20 17 138 10 7 129 16 13 
15.25 Re+5 119 24 20 137 10 8 128 18 14 
20.25 Re+l0 113 29 26 129 * * 118 23 19 
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Table C13 : Arterial blood oxygen partial pressure (mmHg) 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
0 Base 1 92.9 1.3 1 94.4 2.3 2 93 .7 1.8 2 
10 Base2 94.4 1.8 2 97.2 2.0 2 95 .8 2.3 2 
0.25 I+.25 97.4 0.9 1 98.0 1.6 2 97.7 1.2 1 
15 1+15 94.6 1.4 1 96.3 1.0 1 95.5 1.4 1 
0.25 R+.25 96.0 2.1 2 96.1 1.9 2 96.1 1.8 2 
10 R+l0 94.8 1.6 2 94.1 2.6 3 94.5 2.0 2 
20 Re+l0 96.0 * * 92.7 4.6 5 93.5 4.1 4 
0.25 RI+.25 97.4 1.1 1 96.2 4.4 5 96.8 2.9 3 
10 RI+l0 95 .7 2.0 2 95.7 1.8 2 95 .7 1.7 2 
20 Re+l0 94.2 3.1 3 94.6 1.9 2 94.4 2.3 2 
Table Cl 4: Arterial blood carbon dioxide partial pressure (mmHg) 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
0 Base 1 42.5 1.2 3 40.5 4.8 12 41.5 3.3 8 
10 Base 2 43 .0 5.7 13 40.4 3.8 10 41.7 4.6 11 
0.25 I+.25 33.0 7.4 22 33.3 2.6 8 33 .1 5.0 15 
15 1+15 36.8 6.7 18 38.0 5.5 14 37.4 5.5 15 
0.25 R+.25 39.4 4.1 10 37.2 4.2 11 38.3 3.9 10 
10 R+l0 40.9 6.2 15 38.3 3.1 8 39.6 4.6 12 
20 Re+l0 38.9 * * 39.6 2.5 6 39.5 2.1 5 
0.25 RI+.25 33 .2 9.6 29 32.4 3.9 12 32.8 6.5 20 
10 RI+l0 36.8 10.1 27 34.8 2.7 8 35 .8 6.7 19 
20 Re+l0 35 .9 9.7 27 35 .7 2.7 7 35 .8 6.3 18 
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Table C 15 : Arterial blood pH 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
0 Base 1 7.304 0.022 0.3 7.344 0.043 0.6 7.324 0.038 0.5 
10 Base 2 7.333 0.022 0.3 7.379 0.027 0.4 7.356 0.033 0.5 
0.25 I+.25 7.403 0.050 0.7 7.418 0.049 0.7 7.411 0.045 0.6 
15 l+15 7.375 0.060 0.8 7.378 0.060 0.8 7.376 0.053 0.7 
0.25 R+.25 7.350 0.017 0.2 7.383 0.040 0.5 7.367 0.033 0.5 
10 R+l0 7.331 0.024 0.3 7.371 0.043 0.6 7.351 0.038 0.5 
20 Re+l0 7.334 * * 7.365 0.016 0.2 7.358 0.020 0.3 
0.25 RI+.25 7.412 0.076 1.0 7.414 0.059 0.8 7.413 0.061 0.8 
10 RI+l0 7.393 0.076 1.0 7.408 0.026 0.4 7.401 0.051 0.7 
20 Re+l0 7.387 0.067 0.9 7.391 0.022 0.3 7.389 0.045 0.6 
Table C16: Arterial blood hematocrit (percent ofred blood cells in blood) 
Time Event Restriction First Doxapram First Both Sets 
Avg. Sdev. CV Avg. Sdev. CV Avg. Sdev. CV 
0 Base 1 40.7 2.7 7 38.1 3.9 10 39.4 3.3 8 
10 Base 2 42.0 2.6 6 38.7 3.2 8 40.3 3.2 8 
0.25 I+.25 45.2 4.7 10 41.1 4.4 11 43.1 4.6 11 
15 l+15 47.8 3.3 7 42.5 0.4 1 45.1 3.6 8 
0.25 R+.25 41.9 4.3 10 44.9 2.5 6 43.4 3.5 8 
10 R+l0 40.9 6.8 17 43.5 1.9 4 42.2 4.6 11 
20 Re+l0 40.5 * * 45 .2 1.0 2 44.0 2.5 6 
0.25 RI+.25 49.2 4.5 9 43 .9 2.2 5 46.6 4.3 9 
10 RI+lO 49.7 2.9 6 43 .1 5.1 12 46.4 5.2 11 
20 Re+l0 49.3 3.2 6 43 .2 6.2 14 46.2 5.5 12 
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